title,nct_number,locations,lng,lat,drug,source,rank,acronym,status,study_results,conditions,interventions,outcome_measures,sponsor_collaborators,gender,age,phases,enrollment,funded_bys,study_type,study_designs,other_i_ds,start_date,primary_completion_date,completion_date,first_posted,results_first_posted,last_update_posted,study_documents,url,popuptext
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal",-17.4641781,14.6947013,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,1,SEN-CoV-Fadj,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin,SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation,"Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,258,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-002,"June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04390594,"<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal"
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Diamniadio Children Hospital, Diamniadio, Senegal",-17.1636608,14.7268344,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,1,SEN-CoV-Fadj,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin,SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation,"Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,258,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-002,"June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04390594,"<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Diamniadio Children Hospital, Diamniadio, Senegal"
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Dalal Jamm Hospital, Guédiawaye, Senegal",-17.3996674,14.7753661,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,1,SEN-CoV-Fadj,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin,SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation,"Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,258,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-002,"June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04390594,"<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Dalal Jamm Hospital, Guédiawaye, Senegal"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil",-67.8142476,-9.9653701,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital e Clínica São Roque, Ipiaú, BA, Brazil",-39.7355667,-14.138779,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital e Clínica São Roque, Ipiaú, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital da Cidade, Salvador, BA, Brazil",-38.4934735,-12.9571926,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital da Cidade, Salvador, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil",-39.3027232,-7.3119638,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil",-38.498395,-3.8157832,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil",-39.3202759,-7.207309200000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Brasilia, Brasilia, DF, Brazil",-47.8828931,-15.8461712,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Brasilia, Brasilia, DF, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil",-47.9357361,-15.802223,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil",-40.62966410000001,-19.5400456,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil",-40.22743,-20.200262,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil",-40.3431333,-20.3460788,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil",-49.2253596,-16.7313699,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil",-43.9256173,-19.9247413,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Santa Paula, Passos, MG, Brazil",-46.6126084,-20.7135374,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Santa Paula, Passos, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil",-44.2578585,-21.1356146,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil",-46.5559139,-21.8104355,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Universidade Estadual de Londrina, Londrina, Paraná, Brazil",-51.2003547,-23.3241912,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Universidade Estadual de Londrina, Londrina, Paraná, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Adventista de Belém, Belém, Pará, Brazil",-48.4570948,-1.4354138,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Adventista de Belém, Belém, Pará, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Adventista de Belem, Belem, PA, Brazil",-48.4570948,-1.4354138,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Adventista de Belem, Belem, PA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil",-34.8872499,-8.049128399999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil",NA,NA,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil",-35.2260266,-5.797295099999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil",-51.2084876,-30.0250791,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil",-43.2833747,-22.9139074,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Lucas, Rio De Janeiro, RJ, Brazil",-43.1928724,-22.9721921,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital São Lucas, Rio De Janeiro, RJ, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade PROMATER, Natal, RN, Brazil",-35.2164318,-5.823584400000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Maternidade PROMATER, Natal, RN, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil",-51.5108022,-29.17857249999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil",-51.1562243,-29.1611805,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Bruno Born, Lajeado, RS, Brazil",-51.9665968,-29.4631429,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Bruno Born, Lajeado, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil",-52.4132574,-28.2602733,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil",-49.0682555,-26.8801569,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil",-49.3647909,-28.67447589999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Nereu Ramos, Florianópolis, SC, Brazil",-48.533927,-27.577689,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Nereu Ramos, Florianópolis, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil",-48.5183146,-27.5973897,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Centro Hospitalar Unimed, Joinville, SC, Brazil",-48.845416,-26.289832,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Centro Hospitalar Unimed, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Dona Helena, Joinville, SC, Brazil",-48.850613,-26.299132,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Dona Helena, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Municipal Sao Jose, Joinville, SC, Brazil",-48.84623250000001,-26.309458,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Municipal Sao Jose, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil",-48.8127529,-26.2833356,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil",-48.49430539999999,-22.8911069,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil",-47.1110025,-22.9199564,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil",-46.5331357,-23.6709183,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil",-46.6367384,-23.5631726,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Casa de Saude Santa Marcelina, São Paulo, SP, Brazil",-46.3844534,-23.5115075,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Casa de Saude Santa Marcelina, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil",-46.6435635,-23.5690595,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Moriah, São Paulo, SP, Brazil",-46.6602778,-23.615,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Moriah, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Nove de Julho, São Paulo, SP, Brazil",-46.6553318,-23.5594056,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Nove de Julho, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Santa Paula, São Paulo, SP, Brazil",-46.67574159999999,-23.6056726,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Santa Paula, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Camilo Pompeia, São Paulo, SP, Brazil",-46.6882049,-23.5342634,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital São Camilo Pompeia, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação Pio XII, Barretos, São Paulo, Brazil",-48.5706322,-20.5536637,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Fundação Pio XII, Barretos, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil",-49.9780348,-20.4263441,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Israelita Albert Einstein, São Paulo, Brazil",-46.7152547,-23.5999606,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Israelita Albert Einstein, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Associacao Beneficente Siria, São Paulo, Brazil",-46.6165824,-23.4452612,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Associacao Beneficente Siria, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Vila Santa Catarina, São Paulo, Brazil",-46.6535155,-23.6571408,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Hospital Vila Santa Catarina, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil",-46.6684843,-23.5552521,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil",-46.6276663,-23.5950111,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil",-46.6528642,-23.5313723,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Universidade Federal de São Paulo, São Paulo, Brazil",-46.6489943,-23.5916438,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04321278,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</b><br /><i>Recruiting, n = 440</i><br />Universidade Federal de São Paulo, São Paulo, Brazil"
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,NCT04374903,"King Hussein Cancer Center, Amman, Jordan",35.8749208,32.0044797,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,3,COVID19-HOPE,Not yet recruiting,No Results Available,COVID-19 Patients,Drug: HCQ & AZ vs HCQ+SIR,Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance,King Hussein Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20 KHCC 74,"May 1, 2020","August 1, 2020","September 1, 2020","May 5, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04374903,"<b>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients</b><br /><i>Not yet recruiting, n = 58</i><br />King Hussein Cancer Center, Amman, Jordan"
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),NCT04345861,"Montpellier University hospital, Montpellier, France",3.824818499999999,43.6363429,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,4,COVIDOC,Recruiting,No Results Available,"Coronavirus Infection|Pneumonia, Viral",Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin,Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images,"University Hospital, Montpellier",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RECHMPL20_168,"April 11, 2020","September 6, 2020","April 6, 2021","April 15, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04345861,"<b>Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)</b><br /><i>Recruiting, n = 150</i><br />Montpellier University hospital, Montpellier, France"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil",-38.9404,-12.277271,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil",-38.4959327,-12.9572223,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"HHospital SAMUR, Vitória Da Conquista, BA, Brazil",-40.8460076,-14.8626279,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />HHospital SAMUR, Vitória Da Conquista, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil",-40.8502201,-14.8789474,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital de Brasília, Brasilia, DF, Brazil",-47.8699039,-15.7651574,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital de Brasília, Brasilia, DF, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil",-47.9357361,-15.802223,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil",-40.62966410000001,-19.5400456,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Vila da Serra, Nova Lima, MG, Brazil",-43.9441692,-19.9803381,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Vila da Serra, Nova Lima, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil",-44.2578585,-21.1356146,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil",-51.1606506,-23.3266892,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil",-43.1876578,-22.913457,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil",-51.1562243,-29.1611805,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São José, Criciuma, SC, Brazil",-49.3643241,-28.6744925,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São José, Criciuma, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil",-48.54495490000001,-27.6011594,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Nereu Ramos, Florianópolis, Sc, Brazil",-48.533927,-27.577689,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Nereu Ramos, Florianópolis, Sc, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Centro Hospitalar Unimed, Joinville, SC, Brazil",-48.845416,-26.289832,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Centro Hospitalar Unimed, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil",-48.5717864,-20.5545292,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil",-46.4335116,-23.504914,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Albert Einstein, São Paulo, SP, Brazil",-46.7152547,-23.5999606,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Albert Einstein, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil",-46.64310810000001,-23.5674333,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil",-46.6698263,-23.5571357,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil",-46.6540085,-23.5969896,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil",-46.643593,-23.5975138,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Sírio-Libanês, São Paulo, SP, Brazil",-46.6748267,-23.5849389,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Sírio-Libanês, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital SEPACO, São Paulo, S, Brazil",-46.62768819999999,-23.5951605,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04322123,"<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital SEPACO, São Paulo, S, Brazil"
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",NCT04355052,"Sheba Medical Center, Ramat Gan, Israel",34.842852,32.04671,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,7,COSTA,Recruiting,No Results Available,COVID - 19,Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin,clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death,Sheba Medical Center,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,250,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7092-20-SMC,"April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",NA,"April 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04355052,"<b>Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus</b><br /><i>Recruiting, n = 250</i><br />Sheba Medical Center, Ramat Gan, Israel"
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",NCT04355052,"Sheba Medical Center, Tel HaShomer, Israel",34.842852,32.04671,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,7,COSTA,Recruiting,No Results Available,COVID - 19,Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin,clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death,Sheba Medical Center,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,250,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7092-20-SMC,"April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",NA,"April 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04355052,"<b>Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus</b><br /><i>Recruiting, n = 250</i><br />Sheba Medical Center, Tel HaShomer, Israel"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Los Angeles, California, United States",-118.2436849,34.0522342,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Los Angeles, California, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, San Francisco, California, United States",-122.3955966,37.7689296,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, San Francisco, California, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Gainesville, Florida, United States",-82.32482619999999,29.6516344,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Gainesville, Florida, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Chicago, Illinois, United States",-87.6276182,41.8886599,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Chicago, Illinois, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baton Rouge, Louisiana, United States",-91.18714659999999,30.4514677,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baton Rouge, Louisiana, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baltimore, Maryland, United States",-76.6121893,39.2903848,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baltimore, Maryland, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baltimore, Maryland, United States",-76.6121893,39.2903848,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baltimore, Maryland, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Columbia, Missouri, United States",-92.3340724,38.9517053,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Columbia, Missouri, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Chapel Hill, North Carolina, United States",-79.0558445,35.9131996,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Chapel Hill, North Carolina, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Seattle, Washington, United States",-122.3320708,47.6062095,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04358081,"<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Seattle, Washington, United States"
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NCT04347031,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,9,NA,"Active, not recruiting",No Results Available,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,Burnasyan Federal Medical Biophysical Center,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL-01/20,"April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04347031,"<b>A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,NCT04365231,"Hopital Saint Joseph, Marseille, Paca, France",5.393300099999999,43.2753932,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,11,HASCOPT,Not yet recruiting,No Results Available,COVID19,Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients,Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit,"Hospital St. Joseph, Marseille, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HASCOPT2020,April 2020,June 2020,January 2021,"April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365231,"<b>Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial</b><br /><i>Not yet recruiting, n = 50</i><br />Hopital Saint Joseph, Marseille, Paca, France"
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,NCT04329832,"Intermountain Medical Center, Murray, Utah, United States",-111.8950267,40.6579289,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,12,HAHPS,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score,"Intermountain Health Care, Inc.|University of Utah",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051355,"March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04329832,"<b>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19</b><br /><i>Recruiting, n = 300</i><br />Intermountain Medical Center, Murray, Utah, United States"
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,NCT04329832,"University of Utah, Salt Lake City, Utah, United States",-111.8421021,40.7649368,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,12,HAHPS,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score,"Intermountain Health Care, Inc.|University of Utah",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051355,"March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04329832,"<b>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19</b><br /><i>Recruiting, n = 300</i><br />University of Utah, Salt Lake City, Utah, United States"
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,NCT04334382,"Intermountain Medical Center, Murray, Utah, United States",-111.8950267,40.6579289,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,14,HyAzOUT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days,"Intermountain Health Care, Inc.|University of Utah|Utah Department of Health",All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051360,"April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",NA,"April 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04334382,"<b>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</b><br /><i>Recruiting, n = 1550</i><br />Intermountain Medical Center, Murray, Utah, United States"
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,NCT04334382,"University of Utah, Salt Lake City, Utah, United States",-111.8421021,40.7649368,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,14,HyAzOUT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days,"Intermountain Health Care, Inc.|University of Utah|Utah Department of Health",All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051360,"April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",NA,"April 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04334382,"<b>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</b><br /><i>Recruiting, n = 1550</i><br />University of Utah, Salt Lake City, Utah, United States"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Avicenne, Bobigny, France",2.4239471,48.91461940000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04341870,"<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Avicenne, Bobigny, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France",2.2354935,48.84926069999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04341870,"<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Beaujon, Clichy, France",2.3083004,48.9082554,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04341870,"<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Beaujon, Clichy, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Pitié Salpétrière, Paris, France",2.3650429,48.8370792,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04341870,"<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Pitié Salpétrière, Paris, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04341870,"<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Saint Antoine, Paris, France"
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,NCT04348474,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",-46.6322189,-23.6181027,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,16,NA,Suspended,No Results Available,Covid-19,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity,Azidus Brasil,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,200,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIAPRE0420OR,"April 20, 2020","June 30, 2020","July 31, 2020","April 16, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04348474,"<b>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19</b><br /><i>Suspended, n = 200</i><br />Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Saint Barnabas Medical Center, Livingston, New Jersey, United States",-74.3036941,40.7637521,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Saint Barnabas Medical Center, Livingston, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Monmouth Medical Center, Long Branch, New Jersey, United States",-73.98543330000001,40.2954704,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Monmouth Medical Center, Long Branch, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Morristown Medical Center, Morristown, New Jersey, United States",-74.4656519,40.7894006,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Morristown Medical Center, Morristown, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States",-74.450131,40.4952121,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",-74.4486555,40.4965117,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"The University Hospital, Newark, New Jersey, United States",-74.1910884,40.7406294,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />The University Hospital, Newark, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Overlook Hospital, Summit, New Jersey, United States",-74.3536318,40.7127936,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04336332,"<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Overlook Hospital, Summit, New Jersey, United States"
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NCT04346693,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,19,NA,"Active, not recruiting",No Results Available,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study,Burnasyan Federal Medical Biophysical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAL-05-04-2020,"April 8, 2020",December 2020,December 2020,"April 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04346693,"<b>An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,NCT04329572,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",-46.6322189,-23.6181027,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,20,NA,Suspended,No Results Available,COVID-19,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,"Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days",Azidus Brasil,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,400,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIAPRE0320OR,"April 23, 2020","May 31, 2020","June 30, 2020","April 1, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04329572,"<b>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19</b><br /><i>Suspended, n = 400</i><br />Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil"
"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",NCT04359953,"CHU de Strasbourg, Strasbourg, France",7.7462879,48.5764648,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,21,COVID-Aging,Not yet recruiting,No Results Available,COVID-19 Infection,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan,"Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France",All,"60 Years and older   (Adult, Older Adult)",Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7747,"April 24, 2020","June 1, 2021","June 1, 2021","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359953,"<b>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19</b><br /><i>Not yet recruiting, n = 1600</i><br />CHU de Strasbourg, Strasbourg, France"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Alabama CRS, Birmingham, Alabama, United States",-86.8056842,33.5029685,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Alabama CRS, Birmingham, Alabama, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"UCLA CARE Center CRS, Los Angeles, California, United States",-118.4031397,34.0539099,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />UCLA CARE Center CRS, Los Angeles, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Southern California CRS, Los Angeles, California, United States",-118.285117,34.0223519,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Southern California CRS, Los Angeles, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"UCSD Antiviral Research Center CRS, San Diego, California, United States",-117.1658249,32.7555263,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />UCSD Antiviral Research Center CRS, San Diego, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Ucsf Hiv/Aids Crs, San Francisco, California, United States",-122.4561704,37.7641739,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Ucsf Hiv/Aids Crs, San Francisco, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Harbor-UCLA CRS, Torrance, California, United States",-118.2947364,33.8298404,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Harbor-UCLA CRS, Torrance, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Colorado Hospital CRS, Aurora, Colorado, United States",-104.8420288,39.7426294,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Colorado Hospital CRS, Aurora, Colorado, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Whitman-Walker Health CRS, Washington, District of Columbia, United States",-77.0315469,38.9104557,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Whitman-Walker Health CRS, Washington, District of Columbia, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"The Ponce de Leon Center CRS, Atlanta, Georgia, United States",-84.3761076,33.77185300000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />The Ponce de Leon Center CRS, Atlanta, Georgia, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Northwestern University CRS, Chicago, Illinois, United States",-87.6168769,41.8960678,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Northwestern University CRS, Chicago, Illinois, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Rush University CRS, Chicago, Illinois, United States",-87.668852,41.8735131,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Rush University CRS, Chicago, Illinois, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States",-71.067566,42.3626109,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States",-74.189656,40.7400804,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Weill Cornell Chelsea CRS, New York, New York, United States",-73.9932413,40.7441606,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Weill Cornell Chelsea CRS, New York, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Weill Cornell Uptown CRS, New York, New York, United States",-73.954897,40.7649151,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Weill Cornell Uptown CRS, New York, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States",-77.6227808,43.1223345,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Chapel Hill CRS, Chapel Hill, North Carolina, United States",-79.0469134,35.9049122,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Chapel Hill CRS, Chapel Hill, North Carolina, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Greensboro CRS, Greensboro, North Carolina, United States",-79.7919754,36.0726354,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Greensboro CRS, Greensboro, North Carolina, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Cincinnati Clinical Research Site, Cincinnati, Ohio, United States",-84.46758489999999,39.1473527,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Cincinnati Clinical Research Site, Cincinnati, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Case Clinical Research Site, Cleveland, Ohio, United States",-81.620474,41.504468,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Case Clinical Research Site, Cleveland, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Ohio State University CRS, Columbus, Ohio, United States",-83.0306222,40.0068363,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Ohio State University CRS, Columbus, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States",-75.1932137,39.9522188,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States",-79.960835,40.4443533,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States",-71.398257,41.851722,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States",-86.8026551,36.1447034,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Trinity Health and Wellness Center CRS, Dallas, Texas, United States",-96.8254278,32.744499,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Trinity Health and Wellness Center CRS, Dallas, Texas, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Washington AIDS CRS, Seattle, Washington, United States",-122.3035199,47.65533509999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Washington AIDS CRS, Seattle, Washington, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",-66.0522082,18.3966848,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04358068,"<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico"
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,NCT04341207,"Gustave Roussy, Villejuif, Val De Marne, France",2.3484483,48.79425879999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,23,ONCOVID,Recruiting,No Results Available,Cancer & COVID 19,Drug: Hydroxychloroquine|Drug: Azithromycin,Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin,"Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001250-21|2020/3078,"April 3, 2020",April 2022,April 2022,"April 10, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04341207,"<b>Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients</b><br /><i>Recruiting, n = 1000</i><br />Gustave Roussy, Villejuif, Val De Marne, France"
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),NCT04392128,"Institut de Cancérologie Strasbourg Europe, Strasbourg, France",7.7093834,48.5940073,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,25,HYACINTHE,Not yet recruiting,No Results Available,COVID19|Hematologic Malignancy,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule,Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study,Institut de Cancerologie Strasbourg Europe,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-005|2020-002002-45,"May 12, 2020","December 31, 2020","January 31, 2021","May 18, 2020",NA,"May 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04392128,"<b>Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)</b><br /><i>Not yet recruiting, n = 114</i><br />Institut de Cancérologie Strasbourg Europe, Strasbourg, France"
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,NCT04370782,"St Francis Hospital, Roslyn, New York, United States",-73.6702617,40.8046832,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,26,NA,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms,"St. Francis Hospital, New York",All,"30 Years and older   (Adult, Older Adult)",Phase 4,750,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-21,"April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",NA,"May 18, 2020",NA,https://ClinicalTrials.gov/show/NCT04370782,"<b>Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting</b><br /><i>Recruiting, n = 750</i><br />St Francis Hospital, Roslyn, New York, United States"
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",NCT04332094,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,27,TOCOVID,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIBSP-COV-2020-23,"April 2, 2020",September 2020,October 2020,"April 2, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04332094,"<b>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</b><br /><i>Recruiting, n = 276</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke Regional Hospital, Durham, North Carolina, United States",-78.9009425,36.036161,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,28,NA,Recruiting,No Results Available,SARS-CoV-2,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events,Duke University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00105339,"April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335552,"<b>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 500</i><br />Duke Regional Hospital, Durham, North Carolina, United States"
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke University Hospital, Durham, North Carolina, United States",-78.938442,36.0075052,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,28,NA,Recruiting,No Results Available,SARS-CoV-2,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events,Duke University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00105339,"April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335552,"<b>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 500</i><br />Duke University Hospital, Durham, North Carolina, United States"
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Durham VA Medical Center, Durham, North Carolina, United States",-78.9386528,36.0090122,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,28,NA,Recruiting,No Results Available,SARS-CoV-2,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events,Duke University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00105339,"April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335552,"<b>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 500</i><br />Durham VA Medical Center, Durham, North Carolina, United States"
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke Raleigh Hospital, Raleigh, North Carolina, United States",-78.618179,35.8282966,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,28,NA,Recruiting,No Results Available,SARS-CoV-2,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events,Duke University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00105339,"April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335552,"<b>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 500</i><br />Duke Raleigh Hospital, Raleigh, North Carolina, United States"
Azithromycin in Hospitalized COVID-19 Patients,NCT04359316,"Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",51.3980673,35.8001144,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,29,AIC,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events,Shahid Beheshti University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Azithromycin in COVID-19,"April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359316,"<b>Azithromycin in Hospitalized COVID-19 Patients</b><br /><i>Not yet recruiting, n = 40</i><br />Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"
Effectiveness of Hydroxychloroquine in Covid-19 Patients,NCT04328272,"Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",73.2364723,34.2039639,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,30,Covid,Not yet recruiting,No Results Available,COVID19,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets,National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers,"Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad",All,18 Years to 50 Years   (Adult),Phase 3,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Ath/ct101/22/3,"March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",NA,"April 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04328272,"<b>Effectiveness of Hydroxychloroquine in Covid-19 Patients</b><br /><i>Not yet recruiting, n = 75</i><br />Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan"
Asymptomatic COVID-19 Trial,NCT04374552,"Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",-74.450131,40.4952121,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,31,ACT,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo,The primary outcome is the rate of decline in viral load over the 10 days after randomization,"Rutgers, The State University of New Jersey",All,"20 Years and older   (Adult, Older Adult)",Phase 2,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro2020000872,"May 5, 2020",November 2020,April 2021,"May 5, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04374552,"<b>Asymptomatic COVID-19 Trial</b><br /><i>Not yet recruiting, n = 140</i><br />Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States"
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,NCT04354597,"King Hussein Cancer Center, Amman, Jordan",35.8749208,32.0044797,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,32,MOPHYDA,Not yet recruiting,No Results Available,COVID-19,Drug: HCQ & AZ,Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate,King Hussein Cancer Center,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20 KHCC 67,"May 1, 2020","August 15, 2020","October 15, 2020","April 21, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04354597,"<b>Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients</b><br /><i>Not yet recruiting, n = 200</i><br />King Hussein Cancer Center, Amman, Jordan"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hopial Avicenne, Bobigny, France",2.4239471,48.91461940000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hopial Avicenne, Bobigny, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France",2.3522501,48.8105963,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital Saint Antoine, Paris, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Broca, Paris, France",2.347284,48.834292,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital Broca, Paris, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital La Pitié-Salpétrière, Paris, France",2.3650429,48.8370792,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital La Pitié-Salpétrière, Paris, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Cochin, Paris, France",2.3402667,48.8368937,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital Cochin, Paris, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital européen Georges Pompidou, Paris, France",2.2727176,48.8396882,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital européen Georges Pompidou, Paris, France"
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Necker, Paris, France",2.3147044,48.845868,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04344379,"<b>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</b><br /><i>Recruiting, n = 900</i><br />Hôpital Necker, Paris, France"
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NCT04361461,"Apsen Farmacêutica S.A., São Paulo, Brazil",-46.7104346,-23.6477874,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,34,NA,Not yet recruiting,No Results Available,Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation,Apsen Farmaceutica S.A.|Hospital São Paulo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APS001/2020,"May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04361461,"<b>Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)</b><br /><i>Not yet recruiting, n = 500</i><br />Apsen Farmacêutica S.A., São Paulo, Brazil"
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),NCT04363203,"San Francisco VA, San Francisco, California, United States",-122.5052644,37.782395,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,36,VA-REACH,"Active, not recruiting",No Results Available,SARS-CoV-2|COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet,"Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization",Salomeh Keyhani MD|San Francisco VA Health Care System,All,"216 Months and older   (Adult, Older Adult)",Phase 3,300,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20-30517,"April 30, 2020",March 2021,August 2021,"April 27, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04363203,"<b>VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)</b><br /><i>Active, not recruiting, n = 300</i><br />San Francisco VA, San Francisco, California, United States"
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NCT04374019,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",-84.5073963,38.0311683,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,37,NA,Recruiting,No Results Available,COVID|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate,Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function,Susanne Arnold|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-20-COVID-01-PMC,"May 1, 2020",May 2021,May 2021,"May 5, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04374019,"<b>Novel Agents for Treatment of High-risk COVID-19 Positive Patients</b><br /><i>Recruiting, n = 240</i><br />University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Aalborg Sygehus, Aalborg, Denmark",9.9101091,57.03860220000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Aalborg Sygehus, Aalborg, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Bispebjerg Hospital, Copenhagen, Denmark",12.5401313,55.7140142,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Bispebjerg Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Herlev-Gentofte Hospital, Copenhagen, Denmark",12.5467355,55.7388664,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Herlev-Gentofte Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Hvidovre Hospital, Copenhagen, Denmark",12.470292,55.648779,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Hvidovre Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Nordsjællands Hospital, Hillerød, Denmark",12.326221,55.930868,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Nordsjællands Hospital, Hillerød, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Odense Universitetshospital, Odense, Denmark",10.3675736,55.3850091,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Odense Universitetshospital, Odense, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Roskilde Sygehus, Roskilde, Denmark",12.0903485,55.6361646,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Roskilde Sygehus, Roskilde, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Slagelse Sygehus, Slagelse, Denmark",11.370371,55.400234,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020",NA,https://ClinicalTrials.gov/show/NCT04322396,"<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Slagelse Sygehus, Slagelse, Denmark"
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",NCT04344457,"Perseverance Research Center, Scottsdale, Arizona, United States",-111.9264707,33.5871371,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,39,COVID-19,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement,"Perseverance Research Center, LLC|Athena Medical Group",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIZ-PRC-COVID-19,"April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",NA,"April 30, 2020",NA,https://ClinicalTrials.gov/show/NCT04344457,"<b>Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19</b><br /><i>Recruiting, n = 80</i><br />Perseverance Research Center, Scottsdale, Arizona, United States"
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",NCT04344457,"Covidcraz 19, Llc, New Orleans, Louisiana, United States",-90.0715323,29.95106579999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,39,COVID-19,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement,"Perseverance Research Center, LLC|Athena Medical Group",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIZ-PRC-COVID-19,"April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",NA,"April 30, 2020",NA,https://ClinicalTrials.gov/show/NCT04344457,"<b>Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19</b><br /><i>Recruiting, n = 80</i><br />Covidcraz 19, Llc, New Orleans, Louisiana, United States"
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,NCT04344444,"University Medical Center New Orleans, New Orleans, Louisiana, United States",-90.0814661,29.960568,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,40,RCT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Most severe outcome,LCMC Health,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID 2020-001,"April 10, 2020","April 10, 2021","December 10, 2021","April 14, 2020",NA,"April 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04344444,"<b>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease</b><br /><i>Recruiting, n = 600</i><br />University Medical Center New Orleans, New Orleans, Louisiana, United States"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.28119420000002,2.9321351,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.09571559999999,4.648948499999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,NCT04373733,"Chelsea and Westminster Hospital, London, United Kingdom",-0.182401,51.4849533,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,42,PIONEER,Not yet recruiting,No Results Available,Coronavirus Infection,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management,"Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.","Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven",All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CW002|2020-001449-38,"May 1, 2020","March 31, 2021","March 31, 2021","May 4, 2020",NA,"May 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04373733,"<b>A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe</b><br /><i>Not yet recruiting, n = 450</i><br />Chelsea and Westminster Hospital, London, United Kingdom"
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,NCT04373733,"West Middlesex University Hospital, London, United Kingdom",-0.3243212,51.47362889999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,42,PIONEER,Not yet recruiting,No Results Available,Coronavirus Infection,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management,"Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.","Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven",All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CW002|2020-001449-38,"May 1, 2020","March 31, 2021","March 31, 2021","May 4, 2020",NA,"May 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04373733,"<b>A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe</b><br /><i>Not yet recruiting, n = 450</i><br />West Middlesex University Hospital, London, United Kingdom"
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),NCT04351919,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",10.1782429,36.8698022,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,43,COVID+PA,Not yet recruiting,No Results Available,Patients With COVID19,Drug: Hydroxychloroquine|Drug: Azithromycin,improvment or healing of clinical signs|Evolution of clinical signs,Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECC2020-04,"May 5, 2020","July 15, 2020","July 15, 2020","April 17, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04351919,"<b>Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)</b><br /><i>Not yet recruiting, n = 400</i><br />Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia"
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,NCT04339816,"František Duška, Praha, Česká Republika, Czechia",14.4378005,50.0755381,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,44,AZIQUINE-ICU,Recruiting,No Results Available,COVID-19|Respiratory Failure,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo,Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90,"Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic",All,"18 Years and older   (Adult, Older Adult)",Phase 3,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",AZIQUINE-ICU-25032020|2020-001456-18,"May 13, 2020","December 31, 2021","June 30, 2022","April 9, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04339816,"<b>Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial</b><br /><i>Recruiting, n = 240</i><br />František Duška, Praha, Česká Republika, Czechia"
"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",NCT04341727,"Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States",-90.2590677,38.6345957,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,45,WU352,Suspended,No Results Available,Coronavirus Infection,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate,Hours to recovery|Time fever resolution,Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,202003188,"April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04341727,"<b>Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection</b><br /><i>Suspended, n = 500</i><br />Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States"
"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",NCT04341727,"Washington University School of Medicine, Saint Louis, Missouri, United States",-90.26292889999999,38.6351441,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,45,WU352,Suspended,No Results Available,Coronavirus Infection,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate,Hours to recovery|Time fever resolution,Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,202003188,"April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04341727,"<b>Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection</b><br /><i>Suspended, n = 500</i><br />Washington University School of Medicine, Saint Louis, Missouri, United States"
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,NCT04411433,"Hacettepe University, School of Medicine, Ankara, Turkey",32.8631625,39.9303672,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,47,NA,Recruiting,No Results Available,Sars-CoV2|COVID-19,Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin,"Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline","Ministry of Health, Turkey|Hacettepe University, Faculty of Medicine|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Umraniye Education and Research Hospital|SB Istanbul Education and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Kocaeli Derince Education and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19-FAV,"May 8, 2020","July 30, 2020","July 30, 2020","June 2, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04411433,"<b>Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19</b><br /><i>Recruiting, n = 1000</i><br />Hacettepe University, School of Medicine, Ankara, Turkey"
A Study of Quintuple Therapy to Treat COVID-19 Infection,NCT04334512,"ProgenaBiome, Ventura, California, United States",-119.2210602,34.2566277,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,48,HAZDpaC,Not yet recruiting,No Results Available,COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy,ProgenaBiome,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRG-044,May 2020,May 2021,August 2021,"April 6, 2020",NA,"May 12, 2020",NA,https://ClinicalTrials.gov/show/NCT04334512,"<b>A Study of Quintuple Therapy to Treat COVID-19 Infection</b><br /><i>Not yet recruiting, n = 600</i><br />ProgenaBiome, Ventura, California, United States"
Bacteriotherapy in the Treatment of COVID-19,NCT04368351,"Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",12.5144384,41.9037626,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,49,BACT-ovid,"Active, not recruiting",No Results Available,COVID|Pneumonia|Diarrhea,Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine,delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital,University of Roma La Sapienza,All,"18 Years and older   (Adult, Older Adult)",NA,70,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,DPHID-UniRoma05,"March 1, 2020","June 30, 2020","July 31, 2020","April 29, 2020",NA,"May 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04368351,"<b>Bacteriotherapy in the Treatment of COVID-19</b><br /><i>Active, not recruiting, n = 70</i><br />Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy"
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,NCT04390152,"Clinical Somer, Rionegro, Antioquia, Colombia",-75.37751639999999,6.1406917,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,50,NA,Not yet recruiting,No Results Available,Acute Respiratory Distress Syndrome,"Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.",BioXcellerator|Clinical Somer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIOXSOMCOV001,June 2020,November 2020,May 2021,"May 15, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04390152,"<b>Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19</b><br /><i>Not yet recruiting, n = 40</i><br />Clinical Somer, Rionegro, Antioquia, Colombia"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"Chu Angers, Angers, France",-0.5548297,47.4815099,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,51,AziA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion,Nantes University Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC20_0168,"April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",NA,"April 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04363060,"<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />Chu Angers, Angers, France"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"CHD Vendée, La Roche-sur-Yon, France",-1.4118805,46.6677714,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,51,AziA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion,Nantes University Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC20_0168,"April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",NA,"April 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04363060,"<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />CHD Vendée, La Roche-sur-Yon, France"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"CHU Poitiers, Poitiers, France",0.3849052,46.5589271,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,51,AziA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion,Nantes University Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC20_0168,"April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",NA,"April 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04363060,"<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />CHU Poitiers, Poitiers, France"
Double Therapy With IFN-beta 1b and Hydroxychloroquine,NCT04350281,"The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,52,NA,Recruiting,No Results Available,COVID,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes,The University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UW 20-211,"April 9, 2020","March 31, 2022","July 31, 2022","April 17, 2020",NA,"April 17, 2020",NA,https://ClinicalTrials.gov/show/NCT04350281,"<b>Double Therapy With IFN-beta 1b and Hydroxychloroquine</b><br /><i>Recruiting, n = 80</i><br />The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong"
Hydroxychloroquine for COVID-19,NCT04342221,"Institute for Tropical Medicine, Tübingen, Germany",9.0576448,48.5216364,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,53,COV-HCQ,Recruiting,No Results Available,"COVID-19, Hydroxychloroquine Sulfate",Drug: Hydroxychloroquine Sulfate|Drug: Placebo,Effect of HCQ on in vivo viral clearance,University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COV-HCQ|2020-001224-33,"March 29, 2020",March 2021,February 2022,"April 10, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04342221,"<b>Hydroxychloroquine for COVID-19</b><br /><i>Recruiting, n = 220</i><br />Institute for Tropical Medicine, Tübingen, Germany"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States",-87.6771887,41.8746646,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Tulane University, New Orleans, Louisiana, United States",-90.12031669999999,29.9407282,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Tulane University, New Orleans, Louisiana, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Boston University, Boston, Massachusetts, United States",-71.1053991,42.3504997,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Boston University, Boston, Massachusetts, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"NYU Langone Health, New York, New York, United States",-73.9722693,40.746844,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />NYU Langone Health, New York, New York, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"SUNY Upstate Medical University, Syracuse, New York, United States",-76.1395979,43.0422979,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />SUNY Upstate Medical University, Syracuse, New York, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"University of Washington Coordinating Center, Seattle, Washington, United States",-122.3035199,47.65533509999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />University of Washington Coordinating Center, Seattle, Washington, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"UW Virology Research Clinic, Seattle, Washington, United States",-122.3182835,47.6588389,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,"<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />UW Virology Research Clinic, Seattle, Washington, United States"
Patient Preference Trial for COVID-19 (PPT-COVID),NCT04418193,"Centre Hospitalier Princesse Grace, Monaco, Monaco",7.4126981,43.7307715,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,55,PPT-COVID,Recruiting,No Results Available,Coronavirus,NA,"Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older",Centre Hospitalier Princesse Grace,All,"18 Years to 99 Years   (Adult, Older Adult)",NA,100,Other,Observational,Observational Model: Cohort|Time Perspective: Other,20-08,"April 6, 2020","September 1, 2020","September 1, 2020","June 5, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04418193,"<b>Patient Preference Trial for COVID-19 (PPT-COVID)</b><br /><i>Recruiting, n = 100</i><br />Centre Hospitalier Princesse Grace, Monaco, Monaco"
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NCT04343092,"General Directorate of Medical City, Bagdad, Baghdad, Iraq",44.3755185,33.3458996,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,56,NA,Completed,No Results Available,COVID 19,Drug: Ivermectin (IVM),Number of cured patients|Mean time to cure of the covid 19 patients,University of Baghdad,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO20040001,"April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04343092,"<b>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</b><br /><i>Completed, n = 100</i><br />General Directorate of Medical City, Bagdad, Baghdad, Iraq"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Hôpital Privé d'Antony, Antony, France",2.302302,48.7567574,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365582,"<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Hôpital Privé d'Antony, Antony, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Hôpital Avicenne, Bobigny, France",2.4250233,48.9158686,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365582,"<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Hôpital Avicenne, Bobigny, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Centre Hospitalier Intercommunal de Créteil, Créteil, France",2.4654319,48.79640939999999,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365582,"<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Centre Hospitalier Intercommunal de Créteil, Créteil, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Groupe Hospitalier Paris Saint-Joseph, Paris, France",2.3103313,48.829771,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365582,"<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Groupe Hospitalier Paris Saint-Joseph, Paris, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Institut Mutualiste Montsouris, Paris, France",2.3327172,48.822009,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04365582,"<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Institut Mutualiste Montsouris, Paris, France"
Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,NCT04353245,"Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",-46.6698263,-23.5571357,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,58,PostCOVID19,Not yet recruiting,No Results Available,COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia,Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM,Fibrosis|Ergospirometers,University of Sao Paulo General Hospital,All,"18 Years and older   (Adult, Older Adult)",NA,130,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,UAP107,"June 1, 2020","September 30, 2021","September 30, 2021","April 20, 2020",NA,"April 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04353245,"<b>Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System</b><br /><i>Not yet recruiting, n = 130</i><br />Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil"
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,NCT04366089,"Francesco Pugliese, Rome, RM, Italy",12.5134687,41.9627606,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,59,PROBIOZOVID,Recruiting,No Results Available,"COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine",Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin,"Roberto Poscia MD, PhD|Azienda Policlinico Umberto I",All,"18 Years and older   (Adult, Older Adult)",Phase 2,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,110/2020,"March 26, 2020","October 30, 2020","December 31, 2020","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04366089,"<b>Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora</b><br /><i>Recruiting, n = 152</i><br />Francesco Pugliese, Rome, RM, Italy"
Randomised Evaluation of COVID-19 Therapy,NCT04381936,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",-1.2151574,51.7516232,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,60,RECOVERY,Recruiting,No Results Available,Severe Acute Respiratory Syndrome,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab,All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO,"University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding",All,"Child, Adult, Older Adult",Phase 2|Phase 3,12000,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NDPHRECOVERY|2020-001113-21|ISRCTN50189673,"March 19, 2020",December 2020,June 2021,"May 11, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04381936,"<b>Randomised Evaluation of COVID-19 Therapy</b><br /><i>Recruiting, n = 12000</i><br />Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,NCT04324463,"Hamilton Health Sciences, Hamilton, Ontario, Canada",-79.8457682,43.2401034,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,61,ACT COVID19,Recruiting,No Results Available,Coronavirus|Severe Acute Respiratory Syndrome,Drug: Azithromycin|Drug: Hydoxychloroquine or Chloroquine|Drug: Interferon-Beta,Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality,Population Health Research Institute|Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRI.ACT.COVID19,"April 21, 2020","September 30, 2020","December 31, 2020","March 27, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04324463,"<b>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</b><br /><i>Recruiting, n = 1500</i><br />Hamilton Health Sciences, Hamilton, Ontario, Canada"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece",23.828466,38.0463484,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece",23.6423642,37.9701123,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece",25.873962,40.8457193,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece",23.7653267,37.9833862,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece",23.7275388,37.9838096,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece",23.7793555,37.9950485,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece",20.8424173,39.620779,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece",23.6454905,37.9343495,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",22.9600672,40.62955600000001,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020",NA,https://ClinicalTrials.gov/show/NCT04398004,"<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece"
Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,NCT04323345,"Mahmoud Tantawy, Cairo, Egypt",31.2522411,30.053749,HCQ + Azithromycin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,63,NA,Recruiting,No Results Available,COVID-19,Dietary Supplement: Natural Honey|Other: Standard Care,Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results,Misr University for Science and Technology,All,"5 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MUST23032020,"April 15, 2020","December 15, 2020","January 15, 2021","March 26, 2020",NA,"April 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04323345,"<b>Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus</b><br /><i>Recruiting, n = 1000</i><br />Mahmoud Tantawy, Cairo, Egypt"
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NCT04343092,"General Directorate of Medical City, Bagdad, Baghdad, Iraq",44.3755185,33.3458996,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,1,NA,Completed,No Results Available,COVID 19,Drug: Ivermectin (IVM),Number of cured patients|Mean time to cure of the covid 19 patients,University of Baghdad,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO20040001,"April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04343092,"<b>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</b><br /><i>Completed, n = 100</i><br />General Directorate of Medical City, Bagdad, Baghdad, Iraq"
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,NCT04373824,"Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",77.2120291,28.527476,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,2,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin,effect of Ivermectin on eradication of virus.,Max Healthcare Insititute Limited,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MHC-COVID-19- INV- ACT-BHR,"April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",NA,"May 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04373824,"<b>Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study</b><br /><i>Recruiting, n = 50</i><br />Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India"
Efficacy of Ivermectin in COVID-19,NCT04392713,"Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",74.3726762,31.54089309999999,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,3,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin 6 MG Oral Tablet (2 tablets),Negative PCR|Need for mechanical ventilation,"Combined Military Hospital, Pakistan",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVE-COV,"April 15, 2020",July 2020,July 2020,"May 19, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04392713,"<b>Efficacy of Ivermectin in COVID-19</b><br /><i>Recruiting, n = 100</i><br />Combined Military Hospital Lahore, Lahore, Punjab, Pakistan"
Ivermectin and Doxycycine in COVID-19 Treatment,NCT04403555,"Sherief Abd-Elsalam, Tanta, Egypt",31.0023174,30.8055576,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,4,NA,Not yet recruiting,No Results Available,COVID,Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine,The number of patients with resolved viral infection,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,tanta combo covid treatment,"June 1, 2020","December 1, 2030","December 3, 2030","May 27, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04403555,"<b>Ivermectin and Doxycycine in COVID-19 Treatment</b><br /><i>Not yet recruiting, n = 40</i><br />Sherief Abd-Elsalam, Tanta, Egypt"
Prophylactic Ivermectin in COVID-19 Contacts,NCT04422561,"Zagazig University, Zagazig, Sharkia, Egypt",31.4831937,30.5883084,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,5,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin Tablets,"appearance of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)|development of COVID",Zagazig University,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ZU-IRB#6150l31-5-2020,"May 31, 2020",June 2020,July 2020,"June 9, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04422561,"<b>Prophylactic Ivermectin in COVID-19 Contacts</b><br /><i>Recruiting, n = 100</i><br />Zagazig University, Zagazig, Sharkia, Egypt"
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,NCT04351347,"Tanta University, Tanta, Egypt",30.9991409,30.7924391,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,6,NA,Not yet recruiting,No Results Available,COVID,Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin,Number of patients with virological cure,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ivermecin covid,"April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",NA,"April 17, 2020",NA,https://ClinicalTrials.gov/show/NCT04351347,"<b>The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment</b><br /><i>Not yet recruiting, n = 60</i><br />Tanta University, Tanta, Egypt"
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,NCT04399746,"Outpatient treatment, Mexico City, Mexico",-99.133208,19.4326077,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,7,IvAzCol,Recruiting,No Results Available,COVID,Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol,Viral clearance|Symptoms duration|SpO2|SpO2/FiO2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IvAzCol,"March 15, 2020","May 20, 2020","June 10, 2020","May 22, 2020",NA,"May 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04399746,"<b>Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19</b><br /><i>Recruiting, n = 30</i><br />Outpatient treatment, Mexico City, Mexico"
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,NCT04381884,"Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",-58.4053845,-34.5952261,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,8,NA,Recruiting,No Results Available,COVID-19 Drug Treatment,Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2,Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,45,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVM-AR-1,"May 18, 2020","June 30, 2020","June 30, 2020","May 11, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04381884,"<b>Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19</b><br /><i>Recruiting, n = 45</i><br />Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina"
Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,NCT04374279,"Johns Hopkins Hospital, Baltimore, Maryland, United States",-76.59273619999999,39.2967385,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,10,RECOVER,Not yet recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab,Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV2003|IRB00249425,June 2020,June 2021,June 2021,"May 5, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04374279,"<b>Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy</b><br /><i>Not yet recruiting, n = 60</i><br />Johns Hopkins Hospital, Baltimore, Maryland, United States"
New Antiviral Drugs for Treatment of COVID-19,NCT04392427,"Mansoura University, Mansoura, Select A State Or Province, Egypt",31.3589223,31.04099489999999,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,11,NA,Not yet recruiting,No Results Available,COVID|Drug Effect,"Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",negative test result for COVID-19,Mansoura University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,20.05.69,May 2020,May 2022,May 2022,"May 18, 2020",NA,"May 18, 2020",NA,https://ClinicalTrials.gov/show/NCT04392427,"<b>New Antiviral Drugs for Treatment of COVID-19</b><br /><i>Not yet recruiting, n = 100</i><br />Mansoura University, Mansoura, Select A State Or Province, Egypt"
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,NCT04391127,"Jose Manuel Arreola Guerra, Aguascalientes, Mexico",-102.2598747,21.9140456,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,12,NA,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,"Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization",Centenario Hospital Miguel Hidalgo,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2020-A-09,"May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04391127,"<b>Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection</b><br /><i>Recruiting, n = 200</i><br />Jose Manuel Arreola Guerra, Aguascalientes, Mexico"
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,NCT04390022,"Clinica Universidad de Navarra, Pamplona, Navarra, Spain",-1.663439,42.805408,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,15,SAINT,Recruiting,No Results Available,Covid-19|Coronavirus Infection|SARS-CoV-2 Infection,Drug: Ivermectin|Drug: Placebo,"Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health",All,18 Years to 59 Years   (Adult),Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SAINT,"May 14, 2020","August 4, 2020","August 30, 2020","May 15, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04390022,"<b>Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial</b><br /><i>Recruiting, n = 24</i><br />Clinica Universidad de Navarra, Pamplona, Navarra, Spain"
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NCT04374019,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",-84.5073963,38.0311683,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,18,NA,Recruiting,No Results Available,COVID|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate,Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function,Susanne Arnold|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-20-COVID-01-PMC,"May 1, 2020",May 2021,May 2021,"May 5, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04374019,"<b>Novel Agents for Treatment of High-risk COVID-19 Positive Patients</b><br /><i>Recruiting, n = 240</i><br />University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States"
A Real-life Experience on Treatment of Patients With COVID 19,NCT04345419,"Tanta university hospital, Tanta, Egypt",30.9951138,30.80150149999999,Ivermectin,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,19,NA,Not yet recruiting,No Results Available,COVID,Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs,Number of patients with decreased viral load,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,COVID 19 treatment,"April 30, 2020",December 2029,December 2029,"April 14, 2020",NA,"April 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04345419,"<b>A Real-life Experience on Treatment of Patients With COVID 19</b><br /><i>Not yet recruiting, n = 120</i><br />Tanta university hospital, Tanta, Egypt"
"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",NCT04365725,"Hôpital Cochin, Paris, France",2.3402667,48.8368937,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,1,REMDECO-19,Recruiting,No Results Available,COVID-19,Drug: Remdesivir,Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",NA,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP200522,"May 5, 2020",June 2020,June 2020,"April 28, 2020",NA,"May 13, 2020",NA,https://ClinicalTrials.gov/show/NCT04365725,"<b>Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections</b><br /><i>Recruiting, n = 200</i><br />Hôpital Cochin, Paris, France"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic in Arizona, Phoenix, Arizona, United States",-111.9544986,33.6583608,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,2,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,"Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen","ViralClear Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VC-02-01,June 2020,July 2020,August 2020,"June 1, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04410354,"<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic in Arizona, Phoenix, Arizona, United States"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic in Florida, Jacksonville, Florida, United States",-81.44514559999999,30.2626481,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,2,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,"Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen","ViralClear Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VC-02-01,June 2020,July 2020,August 2020,"June 1, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04410354,"<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic in Florida, Jacksonville, Florida, United States"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic, Rochester, Minnesota, United States",-92.46688329999999,44.0226255,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,2,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,"Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen","ViralClear Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VC-02-01,June 2020,July 2020,August 2020,"June 1, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04410354,"<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic, Rochester, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States",-117.8441325,33.8520823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Alta Bates Summit Medical Center, Berkeley, California, United States",-122.2688043,37.8642168,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Alta Bates Summit Medical Center, Berkeley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mills-Peninsula Medical Center, Burlingame, California, United States",-122.3824274,37.59230489999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mills-Peninsula Medical Center, Burlingame, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Eden Medical Center, Castro Valley, California, United States",-122.0888289,37.69798249999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Eden Medical Center, Castro Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States",-118.1288238,33.9191479,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States",-117.4323129,34.0723526,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St Joseph Hospital Eureka, Fortuna, California, United States",-124.1424555,40.7839616,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St Joseph Hospital Eureka, Fortuna, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States",-118.2957816,33.7886375,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States",-118.293899,34.0984583,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States",-118.3750021,34.0383728,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States",-118.5896036,34.1709445,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mission Hospital Regional Medical Center, Mission Viejo, California, United States",-117.6653709,33.5610031,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mission Hospital Regional Medical Center, Mission Viejo, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States",-117.186026,33.897404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"El Camino Hospital, Mountain View, California, United States",-122.0795279,37.3691517,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />El Camino Hospital, Mountain View, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",-117.9296357,33.624397,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, Oakland, California, United States",-122.2582441,37.8235196,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, Oakland, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States",-117.6086894,34.0324565,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States",-117.86362,33.779675,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States",-118.4302294,34.2189257,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States",-117.4694322,33.905076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States",-121.2495341,38.765635,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Medical Center Sacramento, Sacramento, California, United States",-121.4694362,38.57139480000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Medical Center Sacramento, Sacramento, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States",-117.0951878,32.7913395,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States",-117.1251884,32.8297116,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States",-122.4385597,37.6587814,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States",-122.432128,37.7905249,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States",-122.4429971,37.7824144,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States",-121.8002512,37.23980410000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States",-122.1647052,37.7064867,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States",-121.9988333,37.3360472,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Johns Medical Center, Santa Monica, California, United States",-118.4796445,34.0307739,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Johns Medical Center, Santa Monica, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States",-122.7510442,38.4952463,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Stanford Hospital, Stanford, California, United States",-122.1758669,37.4347593,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Stanford Hospital, Stanford, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States",-104.8375727,39.7452818,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Rose Medical Center, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States",-105.086874,39.9699702,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Yale-New Haven Hospital, New Haven, Connecticut, United States",-72.9352096,41.3020731,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Yale-New Haven Hospital, New Haven, Connecticut, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States",-157.9000128,21.3632544,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States",-87.67369,41.8728476,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Rush University Medical Center, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Chicago, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"IU Health Methodist Hospital, Indianapolis, Indiana, United States",-86.1633559,39.7903409,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />IU Health Methodist Hospital, Indianapolis, Indiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",-91.547979,41.658974,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tulane University, New Orleans, Louisiana, United States",-90.12031669999999,29.9407282,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tulane University, New Orleans, Louisiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Maine Medical Center, Portland, Maine, United States",-70.276399,43.6531739,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Maine Medical Center, Portland, Maine, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tufts Medical Center, Boston, Massachusetts, United States",-71.06278259999999,42.3495371,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tufts Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States",-71.1074884,42.3361091,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",-71.1049051,42.3397365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States",-83.72787950000001,42.283286,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Henry Ford Health System, Detroit, Michigan, United States",-83.07581019999999,42.3635022,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hennepin Healthcare, Minneapolis, Minnesota, United States",-93.2615378,44.9722477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hennepin Healthcare, Minneapolis, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mayo Clinic, Rochester, Minnesota, United States",-92.46688329999999,44.0226255,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mayo Clinic, Rochester, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States",-114.0000297,46.8755594,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.67536399999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hackensack University Medical Center, Hackensack, New Jersey, United States",-74.05648819999999,40.8840343,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hackensack University Medical Center, Hackensack, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States",-74.5952861,40.5683581,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States",-74.2125193,40.7100492,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St. Joseph's University Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St. Joseph's University Medical Center, Paterson, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Jacobi Medical Center, Bronx, New York, United States",-73.8463639,40.855993,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Jacobi Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"James J. Peters Veterans Administration Medical Center, Bronx, New York, United States",-73.9064045,40.8674032,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />James J. Peters Veterans Administration Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Danbury Hospital, Lagrangeville, New York, United States",-73.4451577,41.4054443,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Danbury Hospital, Lagrangeville, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"North Shore University Hospital, Manhasset, New York, United States",-73.7013309,40.7752276,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />North Shore University Hospital, Manhasset, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States",-73.70738279999999,40.7543773,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States",-73.941459,40.8409549,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States",-73.9542869,40.7643076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Duke University Medical Center, Durham, North Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States",-122.8767439,45.5394714,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence Portland Medical Center, Portland, Oregon, United States",-122.6127272,45.5275562,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence Portland Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Vincent Medical Center, Portland, Oregon, United States",-122.771627,45.5104546,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Vincent Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Sunnyside Medical Center, Portland, Oregon, United States",-122.5601232,45.4314461,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Sunnyside Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States",-75.19388289999999,39.9501477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",-75.19388289999999,39.9501477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Miriam Hospital, Providence, Rhode Island, United States",-71.398257,41.851722,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Miriam Hospital, Providence, Rhode Island, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prisma Health Richland Hospital, Columbia, South Carolina, United States",-81.0333789,34.0279493,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prisma Health Richland Hospital, Columbia, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States",-82.4109998,34.818455,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States",-96.82346,32.7608903,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, Dallas, Texas, United States",-96.77904799999999,32.7896805,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States",-96.8419366,32.8173287,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States",-97.345412,32.7296877,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Houston Methodist Hospital, Houston, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States",-97.3640532,31.0779405,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Utah Health, Salt Lake City, Utah, United States",-111.8366784,40.77157160000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Utah Health, Salt Lake City, Utah, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Virginia Hospital Center, Arlington, Virginia, United States",-77.127521,38.8891114,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Virginia Hospital Center, Arlington, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Inova Fairfax Medical Campus, Falls Church, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"VCU Health Medical Center, Richmond, Virginia, United States",-77.4299508,37.5408047,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />VCU Health Medical Center, Richmond, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence Regional Medical Center Everett, Everett, Washington, United States",-122.2052146,48.0000596,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence Regional Medical Center Everett, Everett, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kadlec Regional Medical Center, Kennewick, Washington, United States",-119.2822234,46.2813864,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kadlec Regional Medical Center, Kennewick, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Peter Hospital, Olympia, Washington, United States",-122.8479904,47.0529957,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Peter Hospital, Olympia, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Virginia Mason Medical Center, Seattle, Washington, United States",-122.3277093,47.6099974,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Virginia Mason Medical Center, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Swedish Center for Comprehensive Care, Seattle, Washington, United States",-122.32148720000001,47.6063315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Swedish Center for Comprehensive Care, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"MultiCare Deaconess Hospital, Spokane, Washington, United States",-117.4235336,47.6517794,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />MultiCare Deaconess Hospital, Spokane, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"MultiCare Tacoma General Hospital, Tacoma, Washington, United States",-122.45297360000001,47.2593705,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />MultiCare Tacoma General Hospital, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St Joseph Medical Center, Tacoma, Washington, United States",-122.4478581,47.24535830000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St Joseph Medical Center, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China",113.261861,23.113169,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU Pellegrin, Bordeaux, France",-0.6043875,44.8274249,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU Pellegrin, Bordeaux, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France",3.8623414,43.6301844,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU de Nantes-Hotel Dieu, Nantes, France",-1.5545498,47.2107575,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU de Nantes-Hotel Dieu, Nantes, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopital Saint-Louis, Paris, France",2.3672856,48.8771612,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopital Saint-Louis, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopital Saint Antoine, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany",13.3766245,52.5264618,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany",6.792286100000001,51.195064,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany",9.974533,53.59081159999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany",10.1433156,54.3307016,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany",12.375768,51.385368,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany",11.599781,48.13797599999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinik für Hämatologie, Onkologie, Immunologie, München, Germany",11.57756,48.16945,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinik für Hämatologie, Onkologie, Immunologie, München, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany",9.185813999999999,48.815163,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prince of Wales Hospital, Hong Kong, Hong Kong",114.201222,22.378404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prince of Wales Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Princess Margaret Hospital, Hong Kong, Hong Kong",114.1338324,22.3415435,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Princess Margaret Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Queen Mary Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy",9.638066,45.686107,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"ASST degli Spedali Civili di Brescia, Brescia, Italy",10.233707,45.5614101,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />ASST degli Spedali Civili di Brescia, Brescia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy",10.0523058,45.1300126,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy",9.2659593,45.5050198,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy",9.1230078,45.5192174,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",9.197922,45.45888679999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy",11.8880771,45.4015071,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Azienda Ospedaliero Universitaria di Parma, Parma, Italy",10.3083481,44.8016341,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy",9.1488319,45.1962179,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy",9.680999,45.05516129999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy",12.4564793,41.866501,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy",7.659655399999998,45.0889028,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Yokohama Municipal Citizen's Hospital, Kanagawa, Japan",139.604878,35.4688457,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Yokohama Municipal Citizen's Hospital, Kanagawa, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Nagoya City East Medical Center, Nagoya, Japan",136.9436445,35.1738983,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Nagoya City East Medical Center, Nagoya, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan",139.818798,35.6946101,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kyungpook National University Hospital, Daegu, Korea, Republic of",128.6051356,35.865942,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kyungpook National University Hospital, Daegu, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Seoul Medical Center, Seoul, Korea, Republic of",127.0981666,37.6127725,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Seoul Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Medical Center, Seoul, Korea, Republic of",127.0056589,37.5672412,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands",4.959209599999999,52.2938961,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Leiden University Medical Center, Leiden, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Erasmus Medical Centre, Rotterdam, Netherlands",4.467854099999999,51.9108848,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Erasmus Medical Centre, Rotterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National University Hospital, Singapore, Singapore",103.7831756,1.2937278,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National University Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Singapore General Hospital, Singapore, Singapore",103.8348123,1.2804242,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Singapore General Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore",103.8472413,1.3221188,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain",-3.3475567,40.5093672,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain",-8.3879435,43.3444418,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Complejo Hospitalario Universitario A Coruña, A Coruña, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitari Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitari Vall d'Hebron, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitari de Bellvitge, Barcelona, Spain",2.1042573,41.3448959,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitari de Bellvitge, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Cruces, Bizkaia, Spain",-2.983914,43.2820309,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Cruces, Bizkaia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.48760430000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain",-3.7190495,40.43899529999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario 12 de Octubre, Madrid, Spain",-3.6990068,40.3760381,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario 12 de Octubre, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario La Paz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Regional Universitario de Málaga, Málaga, Spain",-4.4498416,36.7231736,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Regional Universitario de Málaga, Málaga, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",-5.9803696,37.3618418,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Virgen del Rocio, Sevilla, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden",11.9614318,57.68236719999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SUS (Skanes University Hospital), Malmo, Sweden",13.0016352,55.589568,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SUS (Skanes University Hospital), Malmo, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Karolinska University Hospital, Stockholm, Sweden",18.030376,59.3482904,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Karolinska University Hospital, Stockholm, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopitaux Universitaires de Genève, Genève 14, Switzerland",6.1490487,46.19331469999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopitaux Universitaires de Genève, Genève 14, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Ospedale Regionale di Locarno La Carità, Lugano, Switzerland",8.7908616,46.1688293,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Ospedale Regionale di Locarno La Carità, Lugano, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitätsspital Zürich, Zürich, Switzerland",8.549177499999999,47.3766158,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitätsspital Zürich, Zürich, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",120.3223407,22.6796829,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"China Medical University Hospital, Taichung, Taiwan",120.6804919,24.1572247,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />China Medical University Hospital, Taichung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Taiwan University Hospital, Taipei City, Taiwan",121.5189863,25.0407391,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Taiwan University Hospital, Taipei City, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom",-0.1743487,51.5178108,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom",-3.1357575,55.9215065,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Infirmary of Edinburgh, Edinburgh, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Queen Elizabeth University Hospital, Glasgow, United Kingdom",-4.340215199999999,55.8628356,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Queen Elizabeth University Hospital, Glasgow, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom",-0.3582799,53.74422029999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Lancaster Hospital, Lancaster, United Kingdom",-2.7995125,54.0423015,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Lancaster Hospital, Lancaster, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Liverpool University Hospital, Liverpool, United Kingdom",-2.9641248,53.4093831,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Liverpool University Hospital, Liverpool, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Northwick Park Hospital, London, United Kingdom",-0.3195181,51.57515009999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Northwick Park Hospital, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Free London NHS Foundation Trust, London, United Kingdom",-0.165596,51.553237,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Free London NHS Foundation Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"King's College Hospital NHS Trust, London, United Kingdom",-0.0938548,51.4681404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />King's College Hospital NHS Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University College London, London, United Kingdom",-0.1340401,51.52455920000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University College London, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",-2.2294865,53.5178824,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Derriford Hospital, Plymouth, United Kingdom",-4.116408,50.4166994,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Derriford Hospital, Plymouth, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sheffield Teaching Hospitals, Sheffield, United Kingdom",-1.4923035,53.379171,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292899,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sheffield Teaching Hospitals, Sheffield, United Kingdom"
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,NCT04252664,"Jin Yin-tan hospital, Wuhan, Hubei, China",114.2868443,30.6668794,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,4,NA,Suspended,No Results Available,COVID-19|SARS-CoV-2,Drug: Remdesivir|Drug: Remdesivir placebo,"Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events",Capital Medical University|Chinese Academy of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAP-China remdesivir 1,"February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",NA,"April 15, 2020",NA,https://ClinicalTrials.gov/show/NCT04252664,"<b>A Trial of Remdesivir in Adults With Mild and Moderate COVID-19</b><br /><i>Suspended, n = 308</i><br />Jin Yin-tan hospital, Wuhan, Hubei, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States",-117.8441325,33.8520823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Alta Bates Summit Medical Center, Berkeley, California, United States",-122.2688043,37.8642168,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Alta Bates Summit Medical Center, Berkeley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mills-Peninsula Medical Center, Burlingame, California, United States",-122.3824274,37.59230489999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mills-Peninsula Medical Center, Burlingame, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Eden Medical Center, Castro Valley, California, United States",-122.0888289,37.69798249999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Eden Medical Center, Castro Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States",-118.1288238,33.9191479,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States",-117.4323129,34.0723526,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St Joseph Hospital Eureka, Fortuna, California, United States",-124.1424555,40.7839616,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St Joseph Hospital Eureka, Fortuna, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States",-118.2957816,33.7886375,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States",-118.293899,34.0984583,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States",-118.3750021,34.0383728,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States",-118.5896036,34.1709445,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mission Hospital Regional Medical Center, Mission Viejo, California, United States",-117.6653709,33.5610031,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mission Hospital Regional Medical Center, Mission Viejo, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States",-117.186026,33.897404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"El Camino Hospital, Mountain View, California, United States",-122.0795279,37.3691517,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />El Camino Hospital, Mountain View, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",-117.9296357,33.624397,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, Oakland, California, United States",-122.2582441,37.8235196,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, Oakland, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States",-117.6086894,34.0324565,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States",-117.86362,33.779675,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States",-118.4302294,34.2189257,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States",-117.4694322,33.905076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States",-121.2495341,38.765635,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Medical Center Sacramento, Sacramento, California, United States",-121.4694362,38.57139480000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Medical Center Sacramento, Sacramento, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States",-117.0951878,32.7913395,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States",-117.1251884,32.8297116,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States",-122.4385597,37.6587814,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States",-122.432128,37.7905249,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States",-122.4429971,37.7824144,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States",-121.8002512,37.23980410000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States",-122.1647052,37.7064867,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States",-121.9988333,37.3360472,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Johns Medical Center, Santa Monica, California, United States",-118.4796445,34.0307739,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Johns Medical Center, Santa Monica, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States",-122.7510442,38.4952463,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Stanford Hospital, Stanford, California, United States",-122.1758669,37.4347593,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Stanford Hospital, Stanford, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States",-104.8375727,39.7452818,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Rose Medical Center, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States",-105.086874,39.9699702,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Yale University, New Haven, Connecticut, United States",-72.92234309999999,41.3163244,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Yale University, New Haven, Connecticut, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States",-157.9000128,21.3632544,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Cook County General Hospital, Chicago, Illinois, United States",-87.67369,41.8728476,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Cook County General Hospital, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Rush University Medical Center, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Chicago, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"IU Health Methodist Hospital, Indianapolis, Indiana, United States",-86.1633559,39.7903409,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />IU Health Methodist Hospital, Indianapolis, Indiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",-91.547979,41.658974,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tulane University, New Orleans, Louisiana, United States",-90.12031669999999,29.9407282,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tulane University, New Orleans, Louisiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Maine Medical Center, Portland, Maine, United States",-70.276399,43.6531739,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Maine Medical Center, Portland, Maine, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tufts Medical Center, Boston, Massachusetts, United States",-71.06278259999999,42.3495371,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tufts Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States",-71.1074884,42.3361091,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",-71.1049051,42.3397365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States",-83.72787950000001,42.283286,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Henry Ford Health System, Detroit, Michigan, United States",-83.07581019999999,42.3635022,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hennepin Healthcare, Minneapolis, Minnesota, United States",-93.2615378,44.9722477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hennepin Healthcare, Minneapolis, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mayo Clinic, Rochester, Minnesota, United States",-92.46688329999999,44.0226255,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mayo Clinic, Rochester, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States",-114.0000297,46.8755594,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.67536399999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hackensack Medical Center, Hackensack, New Jersey, United States",-74.05648819999999,40.8840343,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hackensack Medical Center, Hackensack, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States",-74.5952861,40.5683581,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States",-74.2125193,40.7100492,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St. Joseph's University Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St. Joseph's University Medical Center, Paterson, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Jacobi Medical Center, Bronx, New York, United States",-73.8463639,40.855993,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Jacobi Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"James J. Peters Veterans Administration Medical Center, Bronx, New York, United States",-73.9064045,40.8674032,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />James J. Peters Veterans Administration Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Danbury Hospital, Lagrangeville, New York, United States",-73.4451577,41.4054443,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Danbury Hospital, Lagrangeville, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"North Shore University Hospital, Manhasset, New York, United States",-73.7013309,40.7752276,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />North Shore University Hospital, Manhasset, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States",-73.70738279999999,40.7543773,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",-73.9533616,40.78986949999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Columbia University Irving Medical Center, New York, New York, United States",-73.941459,40.8409549,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Columbia University Irving Medical Center, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States",-73.9542869,40.7643076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Duke University Medical Center, Durham, North Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States",-122.8767439,45.5394714,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence Portland Medical Center, Portland, Oregon, United States",-122.6127272,45.5275562,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence Portland Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Vincent Medical Center, Portland, Oregon, United States",-122.771627,45.5104546,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Vincent Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Sunnyside Medical Center, Portland, Oregon, United States",-122.5601232,45.4314461,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Sunnyside Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States",-75.19388289999999,39.9501477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",-75.19388289999999,39.9501477,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Miriam Hospital, Providence, Rhode Island, United States",-71.398257,41.851722,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Miriam Hospital, Providence, Rhode Island, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prisma Health Richland Hospital, Columbia, South Carolina, United States",-81.0333789,34.0279493,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prisma Health Richland Hospital, Columbia, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States",-82.4109998,34.818455,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States",-96.82346,32.7608903,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, Dallas, Texas, United States",-96.77904799999999,32.7896805,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States",-96.8419366,32.8173287,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States",-97.345412,32.7296877,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Houston Methodist Hospital, Houston, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States",-97.3640532,31.0779405,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Utah Health, Salt Lake City, Utah, United States",-111.8366784,40.77157160000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Utah Health, Salt Lake City, Utah, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Virginia Hospital Center, Arlington, Virginia, United States",-77.127521,38.8891114,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Virginia Hospital Center, Arlington, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Inova Fairfax Hospital, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Inova Fairfax Hospital, Falls Church, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"VCU Health Medical Center, Richmond, Virginia, United States",-77.4299508,37.5408047,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />VCU Health Medical Center, Richmond, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence Medical Research Center, Everett, Washington, United States",-122.2052146,48.0000596,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence Medical Research Center, Everett, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kadlec Regional Medical Center, Kennewick, Washington, United States",-119.2822234,46.2813864,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kadlec Regional Medical Center, Kennewick, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Peter Hospital, Olympia, Washington, United States",-122.8479904,47.0529957,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Peter Hospital, Olympia, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Virginia Mason Medical Center, Seattle, Washington, United States",-122.3277093,47.6099974,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Virginia Mason Medical Center, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Swedish Center for Comprehensive Care, Seattle, Washington, United States",-122.32148720000001,47.6063315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Swedish Center for Comprehensive Care, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"MultiCare Deaconess Hospital, Spokane, Washington, United States",-117.4235336,47.6517794,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />MultiCare Deaconess Hospital, Spokane, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"MultiCare Tacoma General Hospital, Tacoma, Washington, United States",-122.45297360000001,47.2593705,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />MultiCare Tacoma General Hospital, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St Joseph Medical Center, Tacoma, Washington, United States",-122.4478581,47.24535830000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St Joseph Medical Center, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China",113.261861,23.113169,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU Pellegrin, Bordeaux, France",-0.6043875,44.8274249,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU Pellegrin, Bordeaux, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France",3.8623414,43.6301844,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU de Nantes-Hotel Dieu, Nantes, France",-1.5545498,47.2107575,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU de Nantes-Hotel Dieu, Nantes, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopital Saint-Louis, Paris, France",2.3672856,48.8771612,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopital Saint-Louis, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopital Saint Antoine, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany",13.3766245,52.5264618,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany",6.792286100000001,51.195064,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany",9.974533,53.59081159999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany",10.1433156,54.3307016,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany",12.375768,51.385368,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany",11.599781,48.13797599999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinik für Hämatologie, Onkologie, Immunologie, München, Germany",11.57756,48.16945,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinik für Hämatologie, Onkologie, Immunologie, München, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany",9.185813999999999,48.815163,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prince of Wales Hospital, Hong Kong, Hong Kong",114.201222,22.378404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prince of Wales Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Princess Margaret Hospital, Hong Kong, Hong Kong",114.1338324,22.3415435,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Princess Margaret Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Queen Mary Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy",9.638066,45.686107,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST degli Spedali Civili di Brescia, Brescia, Italy",10.233707,45.5614101,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST degli Spedali Civili di Brescia, Brescia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy",10.0523058,45.1300126,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy",9.2659593,45.5050198,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST Fatebenefratelli Sacco, Milano, Italy",9.2190716,45.4847912,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST Fatebenefratelli Sacco, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",9.197922,45.45888679999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy",11.8909972,45.4042074,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Azienda Ospedaliero Universitaria di Parma, Parma, Italy",10.3083481,44.8016341,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",9.1488319,45.1962179,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy",9.680999,45.05516129999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy",12.4564793,41.866501,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy",7.659655399999998,45.0889028,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Yokohama Municipal Citizen's Hospital, Kanagawa, Japan",139.604878,35.4688457,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Yokohama Municipal Citizen's Hospital, Kanagawa, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Nagoya City East Medical Center, Nagoya, Japan",136.9436445,35.1738983,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Nagoya City East Medical Center, Nagoya, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan",139.818798,35.6946101,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kyungpook National University Hospital, Daegu, Korea, Republic of",128.6051356,35.865942,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kyungpook National University Hospital, Daegu, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Seoul Medical Center, Seoul, Korea, Republic of",127.0981666,37.6127725,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Seoul Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Medical Center, Seoul, Korea, Republic of",127.0056589,37.5672412,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands",4.959209599999999,52.2938961,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Leiden University Medical Center, Leiden, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Erasmus Medical Centre, Rotterdam, Netherlands",4.467854099999999,51.9108848,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Erasmus Medical Centre, Rotterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National University Hospital, Singapore, Singapore",103.7831756,1.2937278,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National University Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Singapore General Hospital, Singapore, Singapore",103.8348123,1.2804242,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Singapore General Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore",103.8472413,1.3221188,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain",-3.3475567,40.5093672,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain",-8.3879435,43.3444418,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Complejo Hospitalario Universitario A Coruña, A Coruña, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Vall d'Hebron, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitari de Bellvitge, Barcelona, Spain",2.1042573,41.3448959,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitari de Bellvitge, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Cruces, Bizkaia, Spain",-2.983914,43.2820309,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Cruces, Bizkaia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.48760430000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain",-3.7190495,40.43899529999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario 12 de Octubre, Madrid, Spain",-3.6990068,40.3760381,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario 12 de Octubre, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario La Paz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Regional Universitario de Málaga, Málaga, Spain",-4.4498416,36.7231736,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Regional Universitario de Málaga, Málaga, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",-5.9803696,37.3618418,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Virgen del Rocio, Sevilla, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitari i Politecnic La Fe, Valencia, Spain",-0.3762115,39.44351,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitari i Politecnic La Fe, Valencia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden",11.9614318,57.68236719999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SUS (Skanes University Hospital), Malmo, Sweden",13.0016352,55.589568,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SUS (Skanes University Hospital), Malmo, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Karolinska University Hospital, Stockholm, Sweden",18.030376,59.3482904,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Karolinska University Hospital, Stockholm, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopitaux Universitaires de Genève, Genève 14, Switzerland",6.1490487,46.19331469999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopitaux Universitaires de Genève, Genève 14, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Ospedale Regionale di Locarno La Carità, Lugano, Switzerland",8.7908616,46.1688293,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Ospedale Regionale di Locarno La Carità, Lugano, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitätsspital Zürich, Zürich, Switzerland",8.549177499999999,47.3766158,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitätsspital Zürich, Zürich, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",120.3223407,22.6796829,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"China Medical University Hospital, Taichung, Taiwan",120.6804919,24.1572247,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />China Medical University Hospital, Taichung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Taiwan University Hospital, Taipei City, Taiwan",121.5189863,25.0407391,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Taiwan University Hospital, Taipei City, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Imperial College NHS Trust, London, Greater London, United Kingdom",-0.1743487,51.5178108,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Imperial College NHS Trust, London, Greater London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom",-3.1357575,55.9215065,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Queen Elizabeth University Hospital, Glasgow, United Kingdom",-4.340215199999999,55.8628356,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Queen Elizabeth University Hospital, Glasgow, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom",-0.3582799,53.74422029999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Royal Lancaster Hospital, Lancaster, United Kingdom",-2.7995125,54.0423015,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Royal Lancaster Hospital, Lancaster, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Liverpool University Hospital, Liverpool, United Kingdom",-2.9641248,53.4093831,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Liverpool University Hospital, Liverpool, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Northwick Park Hospital, London, United Kingdom",-0.3195181,51.57515009999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Northwick Park Hospital, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Royal Free London NHS Foundation Trust, London, United Kingdom",-0.165596,51.553237,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Royal Free London NHS Foundation Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"King's College Hospital NHS Trust, London, United Kingdom",-0.0938548,51.4681404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />King's College Hospital NHS Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University College London, London, United Kingdom",-0.1340401,51.52455920000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University College London, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",-2.2294865,53.5178824,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Derriford Hospital, Plymouth, United Kingdom",-4.116408,50.4166994,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Derriford Hospital, Plymouth, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sheffield Teaching Hospitals, Sheffield, United Kingdom",-1.4923035,53.379171,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04292730,"<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sheffield Teaching Hospitals, Sheffield, United Kingdom"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States",-117.024154,32.6172649,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />eStudySite - Chula Vista - PPDS, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States",-93.7608764,32.4807365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Boston Medical Center, Boston, Massachusetts, United States",-71.0731311,42.3344959,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Boston Medical Center, Boston, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Baystate Medical Center, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Baystate Medical Center, Springfield, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"St. Michael'S Medical Center, Newark, New Jersey, United States",-74.17522029999999,40.7443458,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />St. Michael'S Medical Center, Newark, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
A Trial of Remdesivir in Adults With Severe COVID-19,NCT04257656,"Bin Cao, Beijing, Beijing, China",116.4231333,39.942654,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,7,NA,Terminated,No Results Available,COVID-19|Remdesivir|SARS-CoV-2,Drug: Remdesivir|Drug: Remdesivir placebo,Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events,Capital Medical University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,237,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAP-China remdesivir 2,"February 6, 2020","March 30, 2020","April 10, 2020","February 6, 2020",NA,"April 15, 2020",NA,https://ClinicalTrials.gov/show/NCT04257656,"<b>A Trial of Remdesivir in Adults With Severe COVID-19</b><br /><i>Terminated, n = 237</i><br />Bin Cao, Beijing, Beijing, China"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Alabama- Birmingham, Birmingham, Alabama, United States",-86.8064433,33.5019893,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Alabama- Birmingham, Birmingham, Alabama, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Banner- University Medical Center Phoenix, Phoenix, Arizona, United States",-112.0575015,33.4646895,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Banner- University Medical Center Phoenix, Phoenix, Arizona, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Community Regional Medical Centers (CRMC), Fresno, California, United States",-119.7848543,36.742835,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Community Regional Medical Centers (CRMC), Fresno, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Jude Medical Center, Fullerton, California, United States",-117.9272201,33.8943451,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Jude Medical Center, Fullerton, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Scripps Memorial Hospital La Jolla, La Jolla, California, United States",-117.2255426,32.8851578,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Scripps Memorial Hospital La Jolla, La Jolla, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Long Beach Memorial Medical Center, Long Beach, California, United States",-118.1853042,33.8094612,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Long Beach Memorial Medical Center, Long Beach, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Huntington Hospital, Pasadena, California, United States",-118.1521448,34.133943,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Huntington Hospital, Pasadena, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Scripps Mercy Hospital, San Diego, California, United States",-117.1605004,32.7515454,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Scripps Mercy Hospital, San Diego, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"California Pacific Medical Center, San Francisco, California, United States",-122.4347006,37.7683466,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />California Pacific Medical Center, San Francisco, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of California, Medical Center (Parnassus Campus), San Francisco, California, United States",-122.4578922,37.7627248,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of California, Medical Center (Parnassus Campus), San Francisco, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Regional Medical Center, San Jose, California, United States",-121.8497581,37.36277,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Regional Medical Center, San Jose, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"San Mateo Medical Center, San Mateo, California, United States",-122.3003345,37.5308786,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />San Mateo Medical Center, San Mateo, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Santa Rosa Memorial Hospital, Santa Rosa, California, United States",-122.7013876,38.4436202,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Santa Rosa Memorial Hospital, Santa Rosa, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Los Robles Regional Medical Center, Thousand Oaks, California, United States",-118.8832649,34.207655,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Los Robles Regional Medical Center, Thousand Oaks, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"PIH Health Whittier Hospital, Whittier, California, United States",-118.0494059,33.9694666,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />PIH Health Whittier Hospital, Whittier, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Medical Center Of Aurora, Aurora, Colorado, United States",-104.8319627,39.6901471,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Medical Center Of Aurora, Aurora, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rose Medical Center, Denver, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Swedish Medical Center, Englewood, Colorado, United States",-104.9805872,39.6538848,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Swedish Medical Center, Englewood, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Greenwich Hospital, Greenwich, Connecticut, United States",-73.629904,41.0344748,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Greenwich Hospital, Greenwich, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Middlesex Health, Middletown, Connecticut, United States",-72.64706389999999,41.5544714,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Middlesex Health, Middletown, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Hospital of Central Connecticut, New Britain, Connecticut, United States",-72.7867516,41.6613941,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Hospital of Central Connecticut, New Britain, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States",-73.5524563,41.0549124,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"George Washington University Hospital, Washington, District of Columbia, United States",-77.05074119999999,38.901261,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />George Washington University Hospital, Washington, District of Columbia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Aventura Hospital and Medical Center, Aventura, Florida, United States",-80.1457302,25.9702499,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Aventura Hospital and Medical Center, Aventura, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lawnwood Regional Medical Center, Fort Pierce, Florida, United States",-80.34546499999999,27.4318538,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lawnwood Regional Medical Center, Fort Pierce, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Regional Hospital, Hollywood, Florida, United States",-80.1800027,26.0198457,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Regional Hospital, Hollywood, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mayo Clinic in Florida, Jacksonville, Florida, United States",-81.44514559999999,30.2626481,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mayo Clinic in Florida, Jacksonville, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Medical Center, Miami Beach, Florida, United States",-80.14147980000001,25.8130379,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Medical Center, Miami Beach, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States",-81.37075089999999,28.5746404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sarasota Memorial Hospital, Sarasota, Florida, United States",-82.53174,27.3187202,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sarasota Memorial Hospital, Sarasota, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Atlanta Hospital, Atlanta, Georgia, United States",-84.395574,33.8087433,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Atlanta Hospital, Atlanta, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wellstar Atlanta Medical Center, Atlanta, Georgia, United States",-84.3729609,33.76290650000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wellstar Atlanta Medical Center, Atlanta, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States",-84.9818414,32.4805568,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States",-84.3820071,33.751785,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Fayette Hospital, Fayetteville, Georgia, United States",-84.5081318,33.4527476,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Fayette Hospital, Fayetteville, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Health University Medical Center, Savannah, Georgia, United States",-81.088798,32.030295,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Health University Medical Center, Savannah, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"John D. Archbold Memorial Hospital, Thomasville, Georgia, United States",-83.9721278,30.8251693,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />John D. Archbold Memorial Hospital, Thomasville, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Swedish Hospital, Chicago, Illinois, United States",-87.6994788,41.9753719,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Swedish Hospital, Chicago, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Hospital & Medical Center, Chicago, Illinois, United States",-95.71695,37.2253156,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Hospital & Medical Center, Chicago, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States",-87.86523799999999,42.2553365,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Loyola University Medical Center, Maywood, Illinois, United States",-87.8354513,41.860567,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Loyola University Medical Center, Maywood, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States",-88.1562162,41.873256,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States",-86.1442253,39.9821468,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States",-86.1867987,39.77817719999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Riverview Health, Noblesville, Indiana, United States",-86.0234347,40.0460751,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Riverview Health, Noblesville, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States",-91.1075419,30.4040862,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Touro Infirmary, New Orleans, Louisiana, United States",-90.0922393,29.92558989999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Touro Infirmary, New Orleans, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Slidell Memorial Hospital, Slidell, Louisiana, United States",-89.7704122,30.2838293,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Slidell Memorial Hospital, Slidell, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Maryland, Baltimore, Maryland, United States",-76.6257057,39.2892017,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Maryland, Baltimore, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Medical Center, Baltimore, Maryland, United States",-76.612734,39.2930847,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Medical Center, Baltimore, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Calvert Health Medical Center, Prince Frederick, Maryland, United States",-76.5963089,38.5593911,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Calvert Health Medical Center, Prince Frederick, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Maryland St. Joseph Medical Center, Towson, Maryland, United States",-76.6117609,39.3882915,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Maryland St. Joseph Medical Center, Towson, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States",-71.1480227,42.3489047,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Cambridge Health Alliance, Cambridge, Massachusetts, United States",-71.1044036,42.3748656,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Cambridge Health Alliance, Cambridge, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Charlton Memorial Hospital, Fall River, Massachusetts, United States",-71.1462713,41.7099524,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Charlton Memorial Hospital, Fall River, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lawrence General Hospital, Lawrence, Massachusetts, United States",-71.1502191,42.709852,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lawrence General Hospital, Lawrence, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lowell General Hospital, Lowell, Massachusetts, United States",-71.34085,42.647772,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lowell General Hospital, Lowell, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"South Shore Hospital, South Weymouth, Massachusetts, United States",-70.9541728,42.1757238,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />South Shore Hospital, South Weymouth, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UMass Memorial Medical Center, Worcester, Massachusetts, United States",-71.7920244,42.2730591,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UMass Memorial Medical Center, Worcester, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States",-83.65585519999999,42.2650021,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Huron Valley-Sinai Hospital, Commerce, Michigan, United States",-83.49885599999999,42.5925502,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Huron Valley-Sinai Hospital, Commerce, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States",-83.0567987,42.3544796,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Henry Ford Health System, Detroit, Michigan, United States",-83.07581019999999,42.3635022,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"McLaren Health Care Corporation, Flint, Michigan, United States",-83.74224199999999,43.011833,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />McLaren Health Care Corporation, Flint, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Bronson Methodist Hospital, Kalamazoo, Michigan, United States",-85.580433,42.2855115,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Bronson Methodist Hospital, Kalamazoo, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Mississippi Medical Center, Jackson, Mississippi, United States",-90.1736583,32.3299207,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Mississippi Medical Center, Jackson, Mississippi, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Washington University School of Medicine, Saint Louis, Missouri, United States",-90.26292889999999,38.6351441,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Washington University School of Medicine, Saint Louis, Missouri, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States",-74.11237290000001,40.6681687,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Clara Maass Medical Center, Belleville, New Jersey, United States",-74.1764487,40.7856535,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Clara Maass Medical Center, Belleville, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Cooper University Hospital, Camden, New Jersey, United States",-75.1169561,39.9415299,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Cooper University Hospital, Camden, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",-74.3504719,40.5563582,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Trinitas Regional Medical Center, Elizabeth, New Jersey, United States",-74.21450349999999,40.6590205,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Trinitas Regional Medical Center, Elizabeth, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Englewood Health, Englewood, New Jersey, United States",-73.9687157,40.9042797,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Englewood Health, Englewood, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hunterdon Medical Center, Flemington, New Jersey, United States",-74.86113,40.5314853,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hunterdon Medical Center, Flemington, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"CentraState Medical Center, Freehold, New Jersey, United States",-74.3109106,40.2386315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />CentraState Medical Center, Freehold, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States",-74.6716971,40.216006899999996,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jersey City Medical Center, Jersey City, New Jersey, United States",-74.0510031,40.7155777,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jersey City Medical Center, Jersey City, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States",-74.0501141,40.7341106,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Monmouth Medical Center, Long Branch, New Jersey, United States",-73.98543330000001,40.2954704,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Monmouth Medical Center, Long Branch, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States",-74.4656519,40.7894006,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jersey Shore University Medical Center, Neptune, New Jersey, United States",-74.0405748,40.2089489,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jersey Shore University Medical Center, Neptune, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Peter's University Hospital, New Brunswick, New Jersey, United States",-74.4590954,40.5021227,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Peter's University Hospital, New Brunswick, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Michael's Medical Center, Newark, New Jersey, United States",-74.17522029999999,40.7443458,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Michael's Medical Center, Newark, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital, Newark, New Jersey, United States",-74.19019449999999,40.7401785,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital, Newark, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ocean Medical Center, Oakhurst, New Jersey, United States",-74.1316667,40.0769444,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ocean Medical Center, Oakhurst, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Bayshore Medical Center, Red Bank, New Jersey, United States",-74.1917012,40.4054853,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Bayshore Medical Center, Red Bank, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Valley Hospital, Ridgewood, New Jersey, United States",-74.1005112,40.9838774,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Valley Hospital, Ridgewood, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States",-74.3526072,40.7128985,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Holy Name Medical Center, Teaneck, New Jersey, United States",-74.010588,40.8827798,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Holy Name Medical Center, Teaneck, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Capital Health, Trenton, New Jersey, United States",-74.75206039999999,40.2359639,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Capital Health, Trenton, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Virtua Health Voorhees Campus, Voorhees, New Jersey, United States",-74.92752569999999,39.8426668,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Virtua Health Voorhees Campus, Voorhees, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Peter's Hospital, Albany, New York, United States",-73.80371819999999,42.6558325,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Peter's Hospital, Albany, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Queens, Astoria, New York, United States",-73.9248154,40.7680385,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Queens, Astoria, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Good Samaritan Hospital Medical Center, Bay Shore, New York, United States",-73.2944672,40.6940791,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Good Samaritan Hospital Medical Center, Bay Shore, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Southside Hospital, Bay Shore, New York, United States",-73.2415629,40.7258337,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Southside Hospital, Bay Shore, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lincoln Medical Center, Bronx, New York, United States",-73.9243948,40.816972,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lincoln Medical Center, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St Barnabus Hospital, Bronx, New York, United States",-73.8913311,40.8529975,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St Barnabus Hospital, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Montefiore Medical Center, Weiler Campus, Bronx, New York, United States",-73.84583970000001,40.8492061,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Montefiore Medical Center, Weiler Campus, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Montefiore Health System Moses Medical Center, Bronx, New York, United States",-73.88004099999999,40.8804291,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Montefiore Health System Moses Medical Center, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Brooklyn Hospital Center, Brooklyn, New York, United States",-73.9777743,40.691265,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Brooklyn Hospital Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kingsbrook Jewish Medical Center, Brooklyn, New York, United States",-73.9332436,40.6593818,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kingsbrook Jewish Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States",-73.945734,40.6552459,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Woodhull Medical Center, Brooklyn, New York, United States",-73.9425116,40.6996948,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Woodhull Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kings County Hospital Center, Brooklyn, New York, United States",-73.9439771,40.65658699999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kings County Hospital Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Harbor VA Medical Center, Brooklyn, New York, United States",-74.0240443,40.60855,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Harbor VA Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Brookdale University Hospital and Medical Center, Brooklyn, New York, United States",-73.9123577,40.6549713,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Brookdale University Hospital and Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Interfaith Medical Center, Brooklyn, New York, United States",-73.9373439,40.678599,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Interfaith Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States",-73.97842399999999,40.6677145,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Maimonides Medical Center, Brooklyn, New York, United States",-73.9982409,40.6393024,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Maimonides Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States",-74.0208955,40.6467233,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Brooklyn, Brooklyn, New York, United States",-73.94282380000001,40.6187604,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Brooklyn, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States",-73.9648753,40.5855566,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kaleida Health System, Buffalo, New York, United States",-78.8648375,42.9011764,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kaleida Health System, Buffalo, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nassau University Medical Center, East Meadow, New York, United States",-73.554059,40.727212,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nassau University Medical Center, East Meadow, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Presbyterian- Queens, Flushing, New York, United States",-73.8253356,40.7472479,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Presbyterian- Queens, Flushing, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Glens Falls Hospital, Glens Falls, New York, United States",-73.6460742,43.3062687,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Glens Falls Hospital, Glens Falls, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Queens Hospital Center, Jamaica, New York, United States",-73.8044537,40.7169469,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Queens Hospital Center, Jamaica, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NYU Langone Health, New York, New York, United States",-73.9722693,40.746844,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NYU Langone Health, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital for Special Surgery, New York, New York, United States",-73.952559,40.7650229,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital for Special Surgery, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States",-73.9444135,40.7848328,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States",-73.94307839999999,40.8414368,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health + Hospitals / Harlem, New York, New York, United States",-73.93950869999999,40.8143104,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health + Hospitals / Harlem, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Presbyterian Lower Manhattan Hospital, New York, New York, United States",-74.004758,40.7099166,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Presbyterian Lower Manhattan Hospital, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States",-73.9634264,40.7646529,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Sloan-Kettering Cancer Center, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai South Nassau, Oceanside, New York, United States",-73.6305987,40.6519366,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai South Nassau, Oceanside, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States",-73.9357942,41.6943079,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Vassar Brothers Medical Center, Poughkeepsie, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rochester General Hospital, Rochester, New York, United States",-77.5878398,43.1924948,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rochester General Hospital, Rochester, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Francis Hospital, Roslyn, New York, United States",-73.6702617,40.8046832,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Francis Hospital, Roslyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ellis Hospital, Schenectady, New York, United States",-73.916504,42.8200283,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ellis Hospital, Schenectady, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States",-74.086124,40.5847086,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States",-73.1162806,40.908827,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Samaritan Hospital, Troy, New York, United States",-73.67267369999999,42.7340076,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Samaritan Hospital, Troy, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UNC Hospitals, Chapel Hill, North Carolina, United States",-79.0514592,35.9039805,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UNC Hospitals, Chapel Hill, North Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States",-80.8208167,35.2098767,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"MetroHealth Medical Center, Cleveland, Ohio, United States",-81.698272,41.4620817,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />MetroHealth Medical Center, Cleveland, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Ohio State University College of Medicine, Columbus, Ohio, United States",-83.0168242,39.9941487,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Ohio State University College of Medicine, Columbus, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kettering Medical Center, Kettering, Ohio, United States",-84.1910137,39.6975779,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kettering Medical Center, Kettering, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Francis Hospital, Tulsa, Oklahoma, United States",-95.919195,36.072651,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Francis Hospital, Tulsa, Oklahoma, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States",-75.39370079999999,40.6089201,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States",-75.2685264,39.92718540000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St Mary Medical Center, Langhorne, Pennsylvania, United States",-74.9252443,40.2026571,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St Mary Medical Center, Langhorne, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States",-75.2001349,39.94798160000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States",-75.14235339999999,40.0366347,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Allegheny Health Network, Pittsburgh, Pennsylvania, United States",-80.007677,40.4571516,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Allegheny Health Network, Pittsburgh, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UPMC, Pittsburgh, Pennsylvania, United States",-79.9607843,40.4420639,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UPMC, Pittsburgh, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Roger Williams Medical Center,, Providence, Rhode Island, United States",-71.4355842,41.8346224,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Roger Williams Medical Center,, Providence, Rhode Island, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kent Hospital, Warwick, Rhode Island, United States",-71.477898,41.705411,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kent Hospital, Warwick, Rhode Island, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Francis Hospital, Greenville, South Carolina, United States",-82.4214367,34.8403716,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Francis Hospital, Greenville, South Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lexington Medical Center, West Columbia, South Carolina, United States",-81.1135067,34.006705,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lexington Medical Center, West Columbia, South Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"TriStar Centennial Medical Center, Nashville, Tennessee, United States",-86.80927989999999,36.1537953,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />TriStar Centennial Medical Center, Nashville, Tennessee, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. David's South Austin Medical Center, Austin, Texas, United States",-97.7746416,30.2253622,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. David's South Austin Medical Center, Austin, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States",-96.7614722,32.8796103,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"HCA Houston Healthcare West, Houston, Texas, United States",-95.5945083,29.7291522,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />HCA Houston Healthcare West, Houston, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Texas Medical Branch Galveston, League City, Texas, United States",-95.04297160000002,29.5080423,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Texas Medical Branch Galveston, League City, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Covenant Medical Center, Lubbock, Texas, United States",-101.8921,33.576903,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Covenant Medical Center, Lubbock, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Methodist Mansfield Medical Center, Mansfield, Texas, United States",-97.0944701,32.5683689,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Methodist Mansfield Medical Center, Mansfield, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States",-98.572222,29.5078753,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Mark's Hospital, Salt Lake City, Utah, United States",-111.8574151,40.6862543,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Mark's Hospital, Salt Lake City, Utah, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Inova Fairfax Medical Campus, Falls Church, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Henrico Doctors Hospital, Richmond, Virginia, United States",-77.54013599999999,37.6042575,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Henrico Doctors Hospital, Richmond, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Carilion Medical Center, Roanoke, Virginia, United States",-80.0081915,37.3001642,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Carilion Medical Center, Roanoke, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Overlake Hospital Medical Center, Bellevue, Washington, United States",-122.1868308,47.6208557,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Overlake Hospital Medical Center, Bellevue, Washington, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States",-122.3053296,47.6485967,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.02212,43.0429926,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Medical College of Wisconsin, Milwaukee, Wisconsin, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",151.2207522,-33.8805454,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Alfred Hospital, Melbourne, Victoria, Australia",144.9819197,-37.8456704,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Alfred Hospital, Melbourne, Victoria, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Royal Melbourne Hospital, Parkville, Victoria, Australia",144.95617,-37.7989153,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Royal Melbourne Hospital, Parkville, Victoria, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinik für Innere Medizin II, Innsbruck, Austria",11.4041024,47.2692124,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinik für Innere Medizin II, Innsbruck, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kepler Universitätsklinikum, Linz, Austria",14.305467,48.303292,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kepler Universitätsklinikum, Linz, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria",16.3507732,48.1741674,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium",4.345909,50.83448680000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ghent University Hospital, Ghent, Belgium",3.7261488,51.0243757,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ghent University Hospital, Ghent, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jessa Ziekenhuis, Hasselt, Belgium",5.3422505,50.91018529999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jessa Ziekenhuis, Hasselt, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"AZ Groeninge, Kortrijk, Belgium",3.2657973,50.80065440000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />AZ Groeninge, Kortrijk, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitair Ziekenhuis Leuven, Leuven, Belgium",4.6743355,50.8785917,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitair Ziekenhuis Leuven, Leuven, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire de Liège, Liège, Belgium",5.567012699999999,50.5725359,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire de Liège, Liège, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Civil Marie Curie, Lodelinsart, Belgium",4.4390186,50.4307688,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Civil Marie Curie, Lodelinsart, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"William Osler Health System, Brampton, Ontario, Canada",-79.7616899,43.6688351,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />William Osler Health System, Brampton, Ontario, Canada"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Ottowa Hospital, Ottawa, Ontario, Canada",-75.7214357,45.3925787,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Ottowa Hospital, Ottawa, Ontario, Canada"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nicosia General Hospital, Nicosia, Cyprus",33.37701750000001,35.1275993,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nicosia General Hospital, Nicosia, Cyprus"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Všeobecná fakultní nemocnice v Praze, Prague, Czechia",14.421015,50.07339090000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Všeobecná fakultní nemocnice v Praze, Prague, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia",14.3426023,50.0737696,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nemocnice Na Bulovce, Praha 8, Czechia",14.4640562,50.1153757,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nemocnice Na Bulovce, Praha 8, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rigshospitalet, Copenhagen, Denmark",12.5667877,55.6960841,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rigshospitalet, Copenhagen, Denmark"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Põhja-Eesti Regionaalhaigla, Tallinn, Estonia",24.7010389,59.3983667,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Põhja-Eesti Regionaalhaigla, Tallinn, Estonia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Vilnius University, Tartu, Estonia",25.2796514,54.6871555,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Vilnius University, Tartu, Estonia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hopital Avicenne, Bobigny, France",2.4250233,48.9158686,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hopital Avicenne, Bobigny, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France",-4.528394899999999,48.40151090000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France",3.0914286,45.7592004,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpitaux Civils de Colmar, Colmar, France",7.337097,48.0755629,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpitaux Civils de Colmar, Colmar, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Sud Francilien, Corbeil Essonnes, France",2.4563603,48.6205823,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Sud Francilien, Corbeil Essonnes, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Raymond Poincaré, Garches, France",2.1706494,48.838653,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Raymond Poincaré, Garches, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Régional d'Orléans, Orléans, France",1.9206942,47.8361644,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Régional d'Orléans, Orléans, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire de Poitiers, Poitiers, France",0.3849052,46.5589271,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire de Poitiers, Poitiers, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Charles-Nicolle, Rouen, France",1.1070767,49.4409351,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Charles-Nicolle, Rouen, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany",7.2299565,51.49178939999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany",13.7765193,51.0544932,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitatsklinikum, Essen, Germany",6.989008699999999,51.4364493,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitatsklinikum, Essen, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Freiburg, Freiburg, Germany",7.839487399999999,48.0058642,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Freiburg, Freiburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsmedizin Göttingen, Göttingen, Germany",9.9439393,51.5505609,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsmedizin Göttingen, Göttingen, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Medizinische Hochschule Hannover, Hannover, Germany",9.804956899999999,52.3835661,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Medizinische Hochschule Hannover, Hannover, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Heidelberg, Heidelberg, Germany",8.67066,49.41288,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Heidelberg, Heidelberg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum des Saarlandes, Homburg, Germany",7.345822600000001,49.3064546,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum des Saarlandes, Homburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Caritas-Krankenhaus St. Josef, Regensburg, Germany",12.11875,49.0073861,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Caritas-Krankenhaus St. Josef, Regensburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Klinikum Würzburg Mitte, Würzburg, Germany",9.953425,49.7943468,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Klinikum Würzburg Mitte, Würzburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University General Hospital of Patras Panagia I Voithia, Patra, Greece",21.7950459,38.2945759,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University General Hospital of Patras Panagia I Voithia, Patra, Greece"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece",23.0448787,40.6310278,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary",21.6087213,47.5328052,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Landspítali, Reykjavik, Iceland",-21.9273956,64.1384022,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Landspítali, Reykjavik, Iceland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kerry University Hospital, Tralee, Ireland",-9.688643200000001,52.2652569,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kerry University Hospital, Tralee, Ireland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Shaare Zedek Medical Center, Jerusalem, Israel",35.185261,31.773199,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Shaare Zedek Medical Center, Jerusalem, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hasharon Hospital, Petah Tikva, Israel",34.8817607,32.0791871,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hasharon Hospital, Petah Tikva, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel",34.842852,32.04671,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy",13.4547895,43.6019431,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy",16.86185,41.1120624,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria, Bologna, Italy",11.3628626,44.4917102,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria, Bologna, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy",15.0431833,37.5114616,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero - Universitaria Careggi, Florence, Italy",11.2470215,43.8072546,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero - Universitaria Careggi, Florence, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ospedale Policlinico San Martino, Genova, Italy",8.9696536,44.4079103,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ospedale Policlinico San Martino, Genova, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ospedale San Gerardo di Monza, Monza, Italy",9.2586677,45.6024956,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ospedale San Gerardo di Monza, Monza, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliera dei Colli, Napoli, Italy",14.2207009,40.8677625,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliera dei Colli, Napoli, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy",10.395631,43.7217638,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria, Turin, Italy",7.674234499999999,45.0413899,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria, Turin, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Radboud Universitair Medisch Centrum, Nijmegen, Netherlands",5.8611812,51.8235728,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Radboud Universitair Medisch Centrum, Nijmegen, Netherlands"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"HagaZiekenhuis, The Hague, Netherlands",4.2633732,52.0556288,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />HagaZiekenhuis, The Hague, Netherlands"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Szpital Uniwersytecki w Krakowie, Krakow, Poland",19.9530916,50.0619877,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Szpital Uniwersytecki w Krakowie, Krakow, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland",19.4373736,51.8008301,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland",16.9307591,52.4062862,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland",19.0076319,50.1138509,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal",-9.1425133,38.7222155,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal",-8.6195355,41.1472269,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário De São João, Porto, Portugal",-8.6015062,41.18109219999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário De São João, Porto, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania",26.1139908,44.4552889,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania",27.5843775,47.170543,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Clinical hospital for infectious disease, Timisoara, Romania",21.2086793,45.7488716,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Clinical hospital for infectious disease, Timisoara, Romania"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia",21.2554657,48.7078402,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia",14.5216619,46.0541576,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitetni Klinicni Center Maribor, Maribor, Slovenia",15.6487876,46.5517074,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitetni Klinicni Center Maribor, Maribor, Slovenia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitari Germans Trias i Pujol, Badalona, Spain",2.2378635,41.4810618,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitari Germans Trias i Pujol, Badalona, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital General Universitario Gregorio Maranon, Madrid, Spain",-3.6724986,40.4185038,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital General Universitario Gregorio Maranon, Madrid, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Central de Asturias, Oviedo, Spain",-5.8273198,43.3760877,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Central de Asturias, Oviedo, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Son Espases, Palma de Mallorca, Spain",2.6459085,39.6075129,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Son Espases, Palma de Mallorca, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Clinico Universitario de Salamanca, Salamanca, Spain",-5.6754372,40.9637872,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Clinico Universitario de Salamanca, Salamanca, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Donostia, San Sebastian, Spain",-1.9694990000000001,43.292855,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Donostia, San Sebastian, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain",-16.2856164,28.4480627,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Virgen De La Salud, Toledo, Spain",-4.0348853,39.8715417,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Virgen De La Salud, Toledo, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Clinico Universitario de Valladolid, Valladolid, Spain",-4.7196729,41.6556947,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Clinico Universitario de Valladolid, Valladolid, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Miguel Servet, Zaragoza, Spain",-0.8999640999999999,41.6339107,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Miguel Servet, Zaragoza, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kantonsspital Aarau, Aarau, Switzerland",8.060017499999999,47.3890743,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kantonsspital Aarau, Aarau, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital Basel, Basel, Switzerland",7.5830579,47.5621796,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital Basel, Basel, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Spitalzentrum Biel, Biel, Switzerland",7.2445793,47.1468069,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Spitalzentrum Biel, Biel, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kantonsspital Graubünden, Chur, Switzerland",9.538729199999999,46.8640364,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kantonsspital Graubünden, Chur, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland",6.6424293,46.5249174,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Luzerner Kantonsspital, Luzern, Switzerland",8.2974611,47.0576832,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Luzerner Kantonsspital, Luzern, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom",-3.1902577,51.50679580000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Barts Health NHS Trust, London, United Kingdom",-0.0588687,51.5178708,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Barts Health NHS Trust, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",-0.1086417,51.49284189999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. George's Hospital, London, United Kingdom",-0.1752284,51.42656299999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. George's Hospital, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Southampton University Hospital, Southampton, United Kingdom",-1.4344979,50.9331825,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04323761,"<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Southampton University Hospital, Southampton, United Kingdom"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States",-86.8039601,33.503198,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States",-117.225354,32.878285,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States",-118.4466758,34.065656,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States",-117.8887236,33.7871702,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Irvine Medical Center - Infectious Disease, Orange, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States",-122.1402524,37.405063,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States",-122.1743078,37.4379735,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States",-121.4567734,38.5561515,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States",-117.1455806,32.7263636,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States",-122.4050025,37.7561796,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Cedars Sinai Medical Center, West Hollywood, California, United States",-118.3801756,34.075232,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Cedars Sinai Medical Center, West Hollywood, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States",-104.8298306,39.7428484,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States",-104.9910801,39.7282404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States",-82.3497282,29.63757429999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States",-84.27859699999999,33.790841,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States",-84.3115191,33.8016027,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States",-87.62318499999999,41.8947452,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States",-87.67265599999999,41.8705427,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States",-90.0846281,29.9613085,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States",-76.625715,39.2889604,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States",-76.59273619999999,39.2967385,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",-77.09384539999999,39.0016164,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Walter Reed National Military Medical Center, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States",-77.1043789,39.0025272,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States",-71.0688334,42.3631542,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States",-71.76325419999999,42.2777464,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States",-93.2311679,44.9711356,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",-90.231968,38.633482,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States",-95.9759165,41.2548549,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States",-73.8797647,40.8801514,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States",-73.97407369999999,40.7493378,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States",-77.6269403,43.1230503,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States",-78.9430478,36.0076689,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States",-76.674595299999993,40.2643934,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States",-75.19259799999999,39.9476279,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States",-86.80048819999999,36.1424588,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States",-96.8451734,32.8157077,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States",-98.4167342,29.4597886,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Brooke Army Medical Center, Fort Sam Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States",-94.7786557,29.3113831,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",-95.39649899999999,29.71052959999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States",-98.57535209999999,29.5074654,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States",-78.50048509999999,38.0344004,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States",-76.3046348,36.8437973,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States",-122.1786164,47.715878,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Providence Sacred Heart Medical Center, Spokane, Washington, United States",-117.4133073,47.6488744,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Providence Sacred Heart Medical Center, Spokane, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States",-122.55207,47.1097586,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan",139.716339,35.7016562,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of",127.1231772,37.3520673,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Seoul National University Hospital, Seoul, Korea, Republic of",126.9975506,37.57870820000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Seoul National University Hospital, Seoul, Korea, Republic of"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico",-99.1553977,19.2891535,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico",-99.1590142,19.2921803,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National University Health System - Division of Infectious Diseases, Singapore, Singapore",103.7835972,1.2922012,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National University Health System - Division of Infectious Diseases, Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Centre for Infectious Diseases (NCID), Singapore, Singapore",103.8472413,1.3221188,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Centre for Infectious Diseases (NCID), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore",103.9495701,1.3401915,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",103.7453915,1.3337448,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04401579,"<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States",-86.8039601,33.503198,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States",-117.225354,32.878285,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States",-118.4466758,34.065656,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States",-117.8887236,33.7871702,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Irvine Medical Center - Infectious Disease, Orange, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States",-122.1402524,37.405063,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States",-122.1743078,37.4379735,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States",-121.4567734,38.5561515,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States",-117.1455806,32.7263636,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States",-122.4050025,37.7561796,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Cedars Sinai Medical Center, West Hollywood, California, United States",-118.3801756,34.075232,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Cedars Sinai Medical Center, West Hollywood, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States",-104.9910801,39.7282404,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States",-84.27859699999999,33.790841,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States",-87.62318499999999,41.8947452,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States",-87.67265599999999,41.8705427,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States",-90.0846281,29.9613085,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States",-76.625715,39.2889604,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States",-76.59273619999999,39.2967385,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",-77.09384539999999,39.0016164,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Walter Reed National Military Medical Center, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States",-77.1043789,39.0025272,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States",-71.0688334,42.3631542,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States",-71.76325419999999,42.2777464,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States",-93.2311679,44.9711356,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",-90.231968,38.633482,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States",-95.9759165,41.2548549,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States",-73.8797647,40.8801514,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States",-73.97407369999999,40.7493378,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States",-77.6269403,43.1230503,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States",-78.9430478,36.0076689,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States",-76.674595299999993,40.2643934,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States",-75.1928899,39.94708019999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States",-86.80048819999999,36.1424588,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States",-98.4167342,29.4597886,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Brooke Army Medical Center, Fort Sam Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States",-94.7786557,29.3113831,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",-95.39649899999999,29.71052959999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States",-98.57535209999999,29.5074654,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States",-78.50048509999999,38.0344004,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States",-76.3046348,36.8437973,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States",-122.1786164,47.715878,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"The University of Washington - Virology Research Clinic, Seattle, Washington, United States",-122.3182835,47.6588389,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />The University of Washington - Virology Research Clinic, Seattle, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Providence Sacred Heart Medical Center, Spokane, Washington, United States",-117.4133073,47.6488744,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Providence Sacred Heart Medical Center, Spokane, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States",-122.55207,47.1097586,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark",12.5667877,55.6960841,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany",7.1045497,50.7018469,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany",6.9170435,50.92366209999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany",8.6616969,50.0951726,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece",22.9600672,40.62955600000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece",23.7786871,37.968196,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan",139.716339,35.7016562,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of",127.1231772,37.3520673,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",126.9975506,37.57870820000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico",-99.1553977,19.2891535,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico",-99.1590142,19.2921803,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Centre for Infectious Diseases (NCID), Singapore, Singapore",103.8472413,1.3221188,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Centre for Infectious Diseases (NCID), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain",2.1523119,41.3894436,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain",2.2378669,41.48111710000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom",-0.1182958,50.8193472,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom",-0.1188545,51.4990946,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom",-1.6190553,54.98020570000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom",-1.5192863,53.80674800000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"John Radcliffe Hospital, Headington, Oxford, United Kingdom",-1.2188774,51.764391,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04280705,"<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />John Radcliffe Hospital, Headington, Oxford, United Kingdom"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Peter Lougheed Centre, Calgary, Alberta, Canada",-113.9839451,51.0789832,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Peter Lougheed Centre, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Foothills Medical Centre, Calgary, Alberta, Canada",-114.1334883,51.0652154,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Foothills Medical Centre, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Rockyview General Hospital, Calgary, Alberta, Canada",-114.0974163,50.9903099,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Rockyview General Hospital, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"South Health Campus, Calgary, Alberta, Canada",-113.9518929,50.8819537,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />South Health Campus, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"University of Alberta Hopsital, Edmonton, Alberta, Canada",-113.5232015,53.52076340000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />University of Alberta Hopsital, Edmonton, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada",-123.0967667,49.2673536,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St Paul's Hospital, Vancouver, British Columbia, Canada",-123.1280047,49.2806332,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St Paul's Hospital, Vancouver, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada",-123.3279138,48.4327191,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Island Health - Victoria General Hospital, Victoria, British Columbia, Canada",-123.4330644,48.4665044,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Island Health - Victoria General Hospital, Victoria, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",-79.7743193,43.2218746,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St.Joseph's Health Care, London, Ontario, Canada",-81.2548309,43.0009154,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St.Joseph's Health Care, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"University Hospital, London, Ontario, Canada",-81.2745418,43.01245309999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />University Hospital, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Victoria Hospital, London, Ontario, Canada",-81.22543,42.960029,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Victoria Hospital, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",-75.6478786,45.4007275,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Hôpital Montfort, Ottawa, Ontario, Canada",-75.6394863,45.4461659,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Hôpital Montfort, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada",-75.7214357,45.3925787,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Queensway Carleton Hospital, Ottawa, Ontario, Canada",-75.8076141,45.3349843,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Queensway Carleton Hospital, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"North York General Hospital, Toronto, Ontario, Canada",-79.36274410000001,43.7690968,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />North York General Hospital, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",-79.37565959999999,43.7224812,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Toronto Western Hospital, Toronto, Ontario, Canada",-79.4052302,43.6534793,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Toronto Western Hospital, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada",-73.5574486,45.5112735,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada",-73.60157850000002,45.47326229999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"CHU de Québec - Université Laval, Québec, Quebec, Canada",-71.2107848,46.8152117,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />CHU de Québec - Université Laval, Québec, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada",-71.29770549999999,46.7790343,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",-71.880256,45.407037,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04330690,"<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada"
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,NCT04321616,"Andreas Barratt-Due, Oslo, Norway",10.7293142,59.92212860000001,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,12,NA,Recruiting,No Results Available,SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS,Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC,In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction,Oslo University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,118684,"March 28, 2020",August 2020,November 2020,"March 25, 2020",NA,"April 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04321616,"<b>The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients</b><br /><i>Recruiting, n = 700</i><br />Andreas Barratt-Due, Oslo, Norway"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France",2.2558588999999998,49.8728114,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France",6.2427775,49.0836738,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Besançon, Besançon, France",5.962617799999999,47.22530889999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Besançon, Besançon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",-0.6061928,44.829016,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - hôpital Henri-Mondor, Créteil, France",2.4517989,48.7980441,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - hôpital Henri-Mondor, Créteil, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France",5.069147099999999,47.3213803,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Martinique, Fort De France, France",-61.0380384,14.6339646,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Martinique, Fort De France, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France",2.3522501,48.8105963,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalo-Universitaire de Grenoble, La Tronche, France",5.741472,45.202285,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalo-Universitaire de Grenoble, La Tronche, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Lille, Lille, France",3.0347031,50.6108999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Lille, Lille, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hospices Civils de Lyon, Lyon, France",4.8315594,45.7608649,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hospices Civils de Lyon, Lyon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Montpellier, Montpellier, France",3.8504425,43.6315886,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Montpellier, Montpellier, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France",7.341206199999999,47.7387331,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France",6.192022,48.6852009,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Nantes, Nantes, France",-1.5543918,47.2120313,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Nantes, Nantes, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalo-Universitaire de Nice, Nice, France",7.2822826,43.7243711,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalo-Universitaire de Nice, Nice, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Saint Antoine, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France",2.3650429,48.8370792,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Cochin, Paris, France",2.3402667,48.8368937,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Cochin, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France",2.3103313,48.829771,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP- Hôpital Européen Georges-Pompidou, Paris, France",2.2740724,48.8389124,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP- Hôpital Européen Georges-Pompidou, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Bichat Claude Bernard, Paris, France",2.3317094,48.8988449,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Bichat Claude Bernard, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Rennes, Rennes, France",-1.6950482,48.120059500000004,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Rennes, Rennes, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hopital DELAFONTAINE, Saint-Denis, France",2.3711375,48.9335315,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hopital DELAFONTAINE, Saint-Denis, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France",2.4253137,48.843381,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France",4.3629634,45.4820275,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France",7.707166699999999,48.5929237,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France",1.4369245,43.5995462,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Toulouse, Toulouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France",1.4369245,43.5995462,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Toulouse, Toulouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier de Tourcoing, Tourcoing, France",3.1812134,50.743301,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier de Tourcoing, Tourcoing, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Tours, Tours, France",0.6696852999999999,47.3872732,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Tours, Tours, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Annecy Genevois, Épagny, France",6.1175557,45.9338394,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Annecy Genevois, Épagny, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Luxembourg, Luxembourg, Luxembourg",6.100887999999999,49.618558,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Luxembourg, Luxembourg, Luxembourg"
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpitaux Robert Schuman, Luxembourg, Luxembourg",6.176546600000001,49.6323792,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04315948,"<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpitaux Robert Schuman, Luxembourg, Luxembourg"
Sarilumab for Patients With Moderate COVID-19 Disease,NCT04359901,"VA Boston Healthcare System, Boston, Massachusetts, United States",-71.1099407,42.3272945,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,15,NA,Recruiting,No Results Available,COVID,Biological: SARILUMAB,Intubation or death,Westyn Branch-Elliman|VA Boston Healthcare System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 3305,"April 10, 2020",April 2022,April 2023,"April 24, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04359901,"<b>Sarilumab for Patients With Moderate COVID-19 Disease</b><br /><i>Recruiting, n = 120</i><br />VA Boston Healthcare System, Boston, Massachusetts, United States"
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,NCT04405310,"Hospital Nava de Alta Especialidad, Mexico City, Mexico",-99.1285827,19.3244355,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,16,CPC-SARS,Recruiting,No Results Available,COVID-19,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment),"Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DI/20/201/04/19,"May 20, 2020","June 20, 2020","July 20, 2020","May 28, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04405310,"<b>Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial</b><br /><i>Recruiting, n = 80</i><br />Hospital Nava de Alta Especialidad, Mexico City, Mexico"
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,NCT04405310,"Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",-99.1520225,19.4129258,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,16,CPC-SARS,Recruiting,No Results Available,COVID-19,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment),"Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DI/20/201/04/19,"May 20, 2020","June 20, 2020","July 20, 2020","May 28, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04405310,"<b>Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial</b><br /><i>Recruiting, n = 80</i><br />Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.28119420000002,2.9321351,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.09571559999999,4.648948499999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",NCT04373044,"Los Angeles County-USC Medical Center, Los Angeles, California, United States",-118.2075585,34.0575334,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,18,NA,Recruiting,No Results Available,Symptomatic COVID-19 Infection Laboratory-Confirmed,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events,University of Southern California|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,144,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0S-20-3|NCI-2020-02685|P30CA014089,"May 1, 2020","May 1, 2021","May 1, 2022","May 4, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04373044,"<b>Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19</b><br /><i>Recruiting, n = 144</i><br />Los Angeles County-USC Medical Center, Los Angeles, California, United States"
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",NCT04373044,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",-118.2048393,34.0613426,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,18,NA,Recruiting,No Results Available,Symptomatic COVID-19 Infection Laboratory-Confirmed,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events,University of Southern California|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,144,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0S-20-3|NCI-2020-02685|P30CA014089,"May 1, 2020","May 1, 2021","May 1, 2022","May 4, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04373044,"<b>Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19</b><br /><i>Recruiting, n = 144</i><br />USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,19,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04365764,"<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",2.5720537,48.8984523,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,19,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04365764,"<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,NCT04356417,"Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",2.4517989,48.7980441,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,20,TRAPSAH,Not yet recruiting,No Results Available,"AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection",Other: - Synthetic anti-malarial drugs,Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death,Assistance Publique - Hôpitaux de Paris|GIS EPI-PHARE,All,"18 Years and older   (Adult, Older Adult)",NA,6000000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,APHP200412,April 2020,June 2020,June 2020,"April 22, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04356417,"<b>Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse</b><br /><i>Not yet recruiting, n = 6000000</i><br />Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France"
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,NCT04359667,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",15.9801721,45.8297653,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,22,UHID-COVID19,Not yet recruiting,No Results Available,COVID-19|Severe Pneumonia,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab,"University Hospital for Infectious Diseases, Croatia",All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UHID-04,"June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04359667,"<b>Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab</b><br /><i>Not yet recruiting, n = 30</i><br />University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"CNRS, Lyon, France",4.8748526,45.7803551,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,23,OsCOVID19,Not yet recruiting,No Results Available,Covid-19|Corona Virus Infection|SARS-CoV 2,Drug: Oxytocin|Drug: Standard of Care,Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization,Azienda Ospedaliero-Universitaria di Parma|University of Parma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OsCOVID19,"June 3, 2020","October 31, 2020","December 31, 2020","May 13, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04386447,"<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />CNRS, Lyon, France"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy",10.3083481,44.8016341,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,23,OsCOVID19,Not yet recruiting,No Results Available,Covid-19|Corona Virus Infection|SARS-CoV 2,Drug: Oxytocin|Drug: Standard of Care,Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization,Azienda Ospedaliero-Universitaria di Parma|University of Parma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OsCOVID19,"June 3, 2020","October 31, 2020","December 31, 2020","May 13, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04386447,"<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"Ospedale San Francesco, Nuoro, Italy",9.3159735,40.3255781,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,23,OsCOVID19,Not yet recruiting,No Results Available,Covid-19|Corona Virus Infection|SARS-CoV 2,Drug: Oxytocin|Drug: Standard of Care,Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization,Azienda Ospedaliero-Universitaria di Parma|University of Parma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OsCOVID19,"June 3, 2020","October 31, 2020","December 31, 2020","May 13, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04386447,"<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Ospedale San Francesco, Nuoro, Italy"
Convalescent Plasma Therapy in Severe COVID-19 Infection,NCT04403477,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",90.39467669999999,23.739822,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,24,NA,Recruiting,No Results Available,Covid19|Convalescence,Biological: Convalescent plasma,Proportion of In-hospital mortality|Time to death|Fever|Respiratory distress|Saturation of oxygen|Blood pressure|Oxygen requirement|C-reactive Protein|Ferritin|SGPT|SGOT|ICU stay|Ventilator support|Hospital stay|Proportion of Transfusion reaction,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Dhaka Medical College",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BSMMU/2020/6104,"May 20, 2020","July 20, 2020","October 30, 2020","May 27, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04403477,"<b>Convalescent Plasma Therapy in Severe COVID-19 Infection</b><br /><i>Recruiting, n = 20</i><br />Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"
Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients,NCT04395170,"LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia",-75.41626339999999,6.1571707,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,25,NA,Not yet recruiting,No Results Available,Coronavirus Disease 2019 (COVID-19),Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19,Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death,"Lifefactors Zona Franca, SAS",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LFCOLCOVID-19-001,June 2020,December 2020,June 2021,"May 20, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04395170,"<b>Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients</b><br /><i>Not yet recruiting, n = 75</i><br />LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia"
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NCT04361461,"Apsen Farmacêutica S.A., São Paulo, Brazil",-46.7104346,-23.6477874,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,26,NA,Not yet recruiting,No Results Available,Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation,Apsen Farmaceutica S.A.|Hospital São Paulo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APS001/2020,"May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04361461,"<b>Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)</b><br /><i>Not yet recruiting, n = 500</i><br />Apsen Farmacêutica S.A., São Paulo, Brazil"
Early Short Course Corticosteroids in COVID-19,NCT04374071,"Henry Ford Hospital, Detroit, Michigan, United States",-83.0854662,42.3678016,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,27,NA,Completed,No Results Available,"COVID|Pneumonia, Viral",Drug: Methylprednisolone,Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",NA,250,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HFH IRB # 13739,"March 12, 2020","March 27, 2020","April 30, 2020","May 5, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04374071,"<b>Early Short Course Corticosteroids in COVID-19</b><br /><i>Completed, n = 250</i><br />Henry Ford Hospital, Detroit, Michigan, United States"
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,NCT04349410,"FHHI-OI-Camelot; QME, Los Angeles, California, United States",-118.4595285,34.0501689,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,28,FMTVDM,Enrolling by invitation,No Results Available,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status,The Camelot Foundation,All,"Child, Adult, Older Adult",Phase 2|Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FMTVDM2020,"April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",NA,"April 17, 2020",NA,https://ClinicalTrials.gov/show/NCT04349410,"<b>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</b><br /><i>Enrolling by invitation, n = 500</i><br />FHHI-OI-Camelot; QME, Los Angeles, California, United States"
Study of Open Label Losartan in COVID-19,NCT04335123,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05634999999999,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,30,NA,Recruiting,No Results Available,COVID-19,Drug: Losartan,"Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg",University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00145514,"March 25, 2020",September 2020,October 2020,"April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335123,"<b>Study of Open Label Losartan in COVID-19</b><br /><i>Recruiting, n = 50</i><br />University of Kansas Medical Center, Kansas City, Kansas, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Irvine, California, United States",-117.8460245,33.6792494,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Irvine, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Los Angeles, California, United States",-118.318032,34.175903,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Los Angeles, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Reseach Site, San Jose, California, United States",-121.8069487,37.211053,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Reseach Site, San Jose, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Washington, District of Columbia, United States",-77.0368707,38.9071923,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Washington, District of Columbia, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Tampa, Florida, United States",-82.49079259999999,27.937781,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Tampa, Florida, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Peoria, Illinois, United States",-89.6145301,40.7097557,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Peoria, Illinois, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Metairie, Louisiana, United States",-90.1528519,29.9840922,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Metairie, Louisiana, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Baltimore, Maryland, United States",-76.5980261,39.2001672,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Baltimore, Maryland, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Detroit, Michigan, United States",-83.0457538,42.331427,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Detroit, Michigan, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Saint Louis, Missouri, United States",-90.19940419999999,38.6270025,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Saint Louis, Missouri, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, North Las Vegas, Nevada, United States",-115.1499011,36.2093572,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, North Las Vegas, Nevada, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Durham, North Carolina, United States",-78.8662219,35.923193,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Durham, North Carolina, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Fayetteville, North Carolina, United States",-78.87835849999999,35.0526641,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Fayetteville, North Carolina, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Philadelphia, Pennsylvania, United States",-75.1652215,39.9525839,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Philadelphia, Pennsylvania, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",-86.80140089999999,36.1425227,Remdesivir,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020",NA,https://ClinicalTrials.gov/show/NCT04334460,"<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Vanderbilt University Medical Center, Nashville, Tennessee, United States"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy",8.6116796,44.9072727,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy",8.846696999999999,45.6219651,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy",15.0830304,37.5078772,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy",15.0830304,37.5078772,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy",16.2486644,39.293416,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy",8.931986499999999,45.5952076,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Azienda Ospedaliero-Universitaria di Modena, Modena, Italy",10.9421901,44.6363441,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Azienda Ospedaliero-Universitaria di Modena, Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy",10.9421901,44.6363441,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy",10.9421901,44.6363441,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy",10.9421901,44.6363441,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy",10.9252269,44.647128,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy",14.2096027,40.8706618,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"National Cancer Institute, Naples, Italy",14.222673,40.8624762,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />National Cancer Institute, Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy",14.2096027,40.8706618,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy",14.2096027,40.8706618,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy",12.9070597,43.9074642,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy",14.0733013,40.849415,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy",12.1902021,44.4100508,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy",15.6594798,38.1130568,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy",12.5889668,44.04740340000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy",12.4285757,41.93194039999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy",8.8412594,45.8074471,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy",8.8412594,45.8074471,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy",8.8412594,45.8074471,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy",8.8412594,45.8074471,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy",10.9856288,45.4521332,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",10.8394968,45.3474616,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04317092,"<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy"
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,NCT04345445,"University Malaya Medical Centre, Kuala Lumpur, Malaysia",101.6528322,3.1137086,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,2,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Methylprednisolone,The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay,University of Malaya,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TVCS-COVID19,"April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020",NA,"April 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04345445,"<b>Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</b><br /><i>Not yet recruiting, n = 310</i><br />University Malaya Medical Centre, Kuala Lumpur, Malaysia"
"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",NCT04331795,"University of Chicago Medicine, Chicago, Illinois, United States",-87.6042591,41.7887967,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,3,COVIDOSE,Completed,No Results Available,COVID-19,Drug: Tocilizumab,Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 2,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0515,"April 4, 2020","June 5, 2020","June 5, 2020","April 2, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04331795,"<b>Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis</b><br /><i>Completed, n = 32</i><br />University of Chicago Medicine, Chicago, Illinois, United States"
A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,NCT04412772,"Queen's Medical Center, Honolulu, Hawaii, United States",-157.8538531,21.3085481,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,4,ARCHITECTS,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Placebo,Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation,Queen's Medical Centre,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RA-2020-019,"June 1, 2020","December 31, 2021","December 31, 2021","June 2, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04412772,"<b>A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS</b><br /><i>Recruiting, n = 300</i><br />Queen's Medical Center, Honolulu, Hawaii, United States"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel",35.1494106,31.7649503,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,5,NA,Recruiting,No Results Available,Covid19 Pneumonia,Drug: Tocilizumab,Survival,Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-20-HMO-CTIL,"April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04377750,"<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Barzilai Medical Center, Ashkelon, Israel",34.5592871,31.6622785,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,5,NA,Recruiting,No Results Available,Covid19 Pneumonia,Drug: Tocilizumab,Survival,Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-20-HMO-CTIL,"April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04377750,"<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Barzilai Medical Center, Ashkelon, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Wolfson Medical Center, H̱olon, Israel",34.7627074,32.0360309,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,5,NA,Recruiting,No Results Available,Covid19 Pneumonia,Drug: Tocilizumab,Survival,Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-20-HMO-CTIL,"April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04377750,"<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Wolfson Medical Center, H̱olon, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Sheba Medical Center, Ramat Gan, Israel",34.842852,32.04671,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,5,NA,Recruiting,No Results Available,Covid19 Pneumonia,Drug: Tocilizumab,Survival,Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-20-HMO-CTIL,"April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04377750,"<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Sheba Medical Center, Ramat Gan, Israel"
"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",NCT04361032,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",10.1782429,36.8698022,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,6,TRONCHER,Not yet recruiting,No Results Available,COVID19|Intensive Care Unit,Drug: Tocilizumab Injection|Drug: Deferoxamine,the mortality rate,Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECC2020-06,"May 4, 2020","September 4, 2020","October 4, 2020","April 24, 2020",NA,"May 6, 2020",NA,https://ClinicalTrials.gov/show/NCT04361032,"<b>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia</b><br /><i>Not yet recruiting, n = 260</i><br />Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia"
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,NCT04359667,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",15.9801721,45.8297653,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,7,UHID-COVID19,Not yet recruiting,No Results Available,COVID-19|Severe Pneumonia,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab,"University Hospital for Infectious Diseases, Croatia",All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UHID-04,"June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04359667,"<b>Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab</b><br /><i>Not yet recruiting, n = 30</i><br />University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia"
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",NCT04332094,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,8,TOCOVID,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIBSP-COV-2020-23,"April 2, 2020",September 2020,October 2020,"April 2, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04332094,"<b>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</b><br /><i>Recruiting, n = 276</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,NCT04377659,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",-73.9634264,40.7646529,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,9,NA,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab,Progression of respiratory failure or death,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-185,"May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04377659,"<b>Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection</b><br /><i>Recruiting, n = 40</i><br />Memorial Sloan Kettering Cancer Center, New York, New York, United States"
"An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",NCT04424056,"Assistance Publique Hôpitaux de Marseille, Marseille, France",5.3938612,43.2910081,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,10,INFLAMMACOV,Not yet recruiting,No Results Available,Covid19,Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care,Ventilation free days at D28,Assistance Publique Hopitaux De Marseille,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-23,"September 1, 2020","September 30, 2022","November 1, 2022","June 9, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04424056,"<b>An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</b><br /><i>Not yet recruiting, n = 216</i><br />Assistance Publique Hôpitaux de Marseille, Marseille, France"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedale di Guastalla, Guastalla, RE, Italy",10.6672675,44.919041,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedale di Guastalla, Guastalla, RE, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy",10.4497879,44.7060814,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy",8.6214506,44.9152712,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Policlinico Sant'Orsola Malpighi, Bologna, Italy",11.3604497,44.4927201,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Policlinico Sant'Orsola Malpighi, Bologna, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Cremona, Cremona, Italy",10.0523058,45.1300126,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Cremona, Cremona, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy",7.5366136,44.3853584,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy",11.6963026,44.7998971,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero Universitaria Careggi, Firenze, Italy",11.2476977,43.8072701,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero Universitaria Careggi, Firenze, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedale Evangelico Internazionale di Genova, Genova, Italy",8.9429838,44.414108,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedale Evangelico Internazionale di Genova, Genova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy",8.0119012,43.8802392,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy",9.832067799999999,44.1118233,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Mantova - Ospedale Carlo Poma, Mantova, Italy",10.7732402,45.1448334,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Mantova - Ospedale Carlo Poma, Mantova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"IRCCS Istituto Auxologico Italiano Milano, Milano, Italy",9.145011,45.471875,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />IRCCS Istituto Auxologico Italiano Milano, Milano, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy",8.621986999999999,45.44200379999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy",11.8846965,45.4127245,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero-Universitaria Parma, Parma, Italy",10.3083481,44.8016341,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero-Universitaria Parma, Parma, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy",9.700031899999999,45.0570706,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera Universitaria Pisana, Pisa, Italy",10.4432297,43.7064336,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AO Ordine Mauriziano di Torino, Torino, Italy",7.664954099999999,45.0524366,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AO Ordine Mauriziano di Torino, Torino, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Bergamo Ovest -Treviglio, Treviglio, Italy",9.6111994,45.5101004,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Bergamo Ovest -Treviglio, Treviglio, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS 2 Marca Trevigiana, Treviso, Italy",12.2644188,45.6612591,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS 2 Marca Trevigiana, Treviso, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy",12.3197938,45.9873685,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy",12.2232083,45.513721,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy",10.9856288,45.4521332,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"IRCCS Sacro Cuore Don Calabria, Verona, Italy",10.9359529,45.5303486,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04346355,"<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />IRCCS Sacro Cuore Don Calabria, Verona, Italy"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"University Hospital Bern (Inselspital), Bern, Switzerland",7.4247343,46.947267600000004,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,12,CORON-ACT,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Tocilizumab (TCZ)|Drug: Placebo,Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days),"University Hospital Inselspital, Berne|Roche Pharma AG",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-00691|2020DR2044,"April 26, 2020",October 2020,October 2020,"April 6, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04335071,"<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />University Hospital Bern (Inselspital), Bern, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland",6.6424293,46.5249174,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,12,CORON-ACT,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Tocilizumab (TCZ)|Drug: Placebo,Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days),"University Hospital Inselspital, Berne|Roche Pharma AG",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-00691|2020DR2044,"April 26, 2020",October 2020,October 2020,"April 6, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04335071,"<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"Ospedale Regionale di Lugano (EOC), Viganello, Switzerland",8.9606,46.0098198,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,12,CORON-ACT,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Tocilizumab (TCZ)|Drug: Placebo,Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days),"University Hospital Inselspital, Berne|Roche Pharma AG",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-00691|2020DR2044,"April 26, 2020",October 2020,October 2020,"April 6, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04335071,"<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />Ospedale Regionale di Lugano (EOC), Viganello, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"University Hospital Zurich, Zurich, Switzerland",8.549177499999999,47.3766158,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,12,CORON-ACT,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Tocilizumab (TCZ)|Drug: Placebo,Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days),"University Hospital Inselspital, Berne|Roche Pharma AG",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-00691|2020DR2044,"April 26, 2020",October 2020,October 2020,"April 6, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04335071,"<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />University Hospital Zurich, Zurich, Switzerland"
"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",NCT04412291,"Karolinska University Hospital, Huddinge, Stockholm, Sweden",18.030376,59.3482904,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,13,NA,Not yet recruiting,No Results Available,Covid-19,Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment,"Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from admission using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to change in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of days of hospitalization in survivors|Number of deaths due to any cause",Jon Lampa|Karolinska University Hospital|Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001748-24,June 2020,August 2020,February 2021,"June 2, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04412291,"<b>A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study</b><br /><i>Not yet recruiting, n = 120</i><br />Karolinska University Hospital, Huddinge, Stockholm, Sweden"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"UNIFESP, São Paulo, Sao Paulo, Brazil",-46.6489943,-23.5916438,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />UNIFESP, São Paulo, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil",-46.6436478,-23.5729864,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil",-46.6435635,-23.5690595,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil",-46.6419505,-23.5664177,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil",-46.638029,-23.562,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil",-46.7152547,-23.5999606,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HSL - Hospital Sírio Libanês, Sao Paulo, Brazil",-46.6537114,-23.5572749,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04403685,"<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HSL - Hospital Sírio Libanês, Sao Paulo, Brazil"
Efficacy of Tocilizumab on Patients With COVID-19,NCT04356937,"Massachusetts General Hospital, Boston, Massachusetts, United States",-71.067566,42.3626109,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,15,NA,Not yet recruiting,No Results Available,SARS-CoV 2,Drug: Tocilizumab|Drug: Placebos,Proportion of patients that require mechanical ventilation|Requirement for inotropes and/or vasopressors|8-level Clinical improvement Scale|Duration of mechanical ventalition|Hospital discharge|Mortality|Duration of ICU stay|Duration of time on supplemental oxygen|The proportion of patients who require renal replacement therapy or have doubling of creatinine,"Massachusetts General Hospital|Genentech, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2020P001159,"April 27, 2020","June 30, 2020","August 30, 2020","April 22, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04356937,"<b>Efficacy of Tocilizumab on Patients With COVID-19</b><br /><i>Not yet recruiting, n = 300</i><br />Massachusetts General Hospital, Boston, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States",-112.0575015,33.4646895,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Univ of AZ Coll of Med, Tucson, Arizona, United States",-110.9461054,32.2410865,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Univ of AZ Coll of Med, Tucson, Arizona, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Scripps Mercy Hospital, Chula Vista, California, United States",-117.083637,32.633558,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Scripps Mercy Hospital, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"El Centro Regional Medical Center, El Centro, California, United States",-115.5684684,32.7802257,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />El Centro Regional Medical Center, El Centro, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"eStudySite, La Mesa, California, United States",-117.0094774,32.7804422,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />eStudySite, La Mesa, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Riverside University Health System-Medical Center, Moreno Valley, California, United States",-117.1960044,33.91217779999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Riverside University Health System-Medical Center, Moreno Valley, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Highland Hospital Oakland, Oakland, California, United States",-122.2321344,37.79890170000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Highland Hospital Oakland, Oakland, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States",-122.1428781,37.7127151,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Yale University School Of Medicine, New Haven, Connecticut, United States",-72.9338698,41.30323,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Yale University School Of Medicine, New Haven, Connecticut, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Howard University, Washington, District of Columbia, United States",-77.0204624,38.92121710000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Howard University, Washington, District of Columbia, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Westchester General Hospital, Miami, Florida, United States",-80.31765469999999,25.747314,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Westchester General Hospital, Miami, Florida, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Columbus Regional Research Institute, Columbus, Georgia, United States",-84.9600928,32.5268217,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Columbus Regional Research Institute, Columbus, Georgia, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Uni of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05634999999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Uni of Kansas Medical Center, Kansas City, Kansas, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Ochsner Clinic, New Orleans, Louisiana, United States",-90.1436859,29.9631002,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Ochsner Clinic, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"LSU-Shreveport, Shreveport, Louisiana, United States",-93.7034604,32.4284824,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />LSU-Shreveport, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Holy Cross Germantown Hospital, Germantown, Maryland, United States",-77.2424097,39.1817574,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Holy Cross Germantown Hospital, Germantown, Maryland, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Henry Ford Health System, Detroit, Michigan, United States",-83.07581019999999,42.3635022,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Henry Ford Health System, Detroit, Michigan, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Optum Health Care, Las Vegas, Nevada, United States",-115.122352,36.114124,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Optum Health Care, Las Vegas, Nevada, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"San Juan Oncology Associates, Farmington, New Mexico, United States",-108.2160998,36.7265744,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />San Juan Oncology Associates, Farmington, New Mexico, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"St. Barnabas Hospital, Bronx, New York, United States",-73.8913311,40.8529975,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />St. Barnabas Hospital, Bronx, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Kings County Hospital Center, Brooklyn, New York, United States",-73.9439771,40.65658699999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Kings County Hospital Center, Brooklyn, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"SUNY Downstate Medical Center., Brooklyn, New York, United States",-73.9456988,40.65529340000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />SUNY Downstate Medical Center., Brooklyn, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Elmhurst Hospital Center, Elmhurst, New York, United States",-73.8857314,40.74516939999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Elmhurst Hospital Center, Elmhurst, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Flushing Hospital, Flushing, New York, United States",-73.8166076,40.7551189,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Flushing Hospital, Flushing, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Harlem Hospital, New York, New York, United States",-73.93950869999999,40.8143104,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Harlem Hospital, New York, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Canton-Potsdam Hospital, Potsdam, New York, United States",-74.9825672,44.6764714,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Canton-Potsdam Hospital, Potsdam, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Sanford Health System, Sioux Falls, South Dakota, United States",-96.7431672,43.5356179,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Sanford Health System, Sioux Falls, South Dakota, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.0706558,43.17515179999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020",NA,https://ClinicalTrials.gov/show/NCT04372186,"<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of California San Diego, La Jolla, California, United States",-117.2340135,32.8800604,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of California San Diego, La Jolla, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"eStudySite, La Mesa, California, United States",-117.0094774,32.7804422,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />eStudySite, La Mesa, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"David Geffen School of Medicine UCLA, Los Angeles, California, United States",-118.4423562,34.06428289999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />David Geffen School of Medicine UCLA, Los Angeles, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Stanford University, Stanford, California, United States",-122.169719,37.4274745,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Stanford University, Stanford, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Denver Health Medical Center, Denver, Colorado, United States",-104.9910801,39.7282404,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Denver Health Medical Center, Denver, Colorado, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of Miami Miller School of Medicine, Miami, Florida, United States",-80.21199279999999,25.7904064,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of Miami Miller School of Medicine, Miami, Florida, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Rush University Medical Center, Chicago, Illinois, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of Chicago, Chicago, Illinois, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States",-90.99998509999999,30.442823,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Baystate Health System, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Baystate Health System, Springfield, Massachusetts, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Mayo Clinic - PPDS, Rochester, Minnesota, United States",-92.46688329999999,44.0226255,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Mayo Clinic - PPDS, Rochester, Minnesota, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hackensack University Medical Center, Hackensack, New Jersey, United States",-74.05648819999999,40.8840343,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hackensack University Medical Center, Hackensack, New Jersey, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States",-73.9064045,40.8674032,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Duke University Medical Center, Durham, North Carolina, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States",-81.6211125,41.5025982,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",-75.1560106,39.9478658,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Thomas Jefferson University, Philadelphia, Pennsylvania, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Baylor St. Luke's Medical Center, Houston, Texas, United States",-95.40062239999999,29.707705700000002,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Baylor St. Luke's Medical Center, Houston, Texas, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Ben Taub General Hospital - HCHD, Houston, Texas, United States",-95.3933462,29.71064059999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Ben Taub General Hospital - HCHD, Houston, Texas, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Intermountain Medical Group, Saint George, Utah, United States",-113.5539707,37.0968017,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Intermountain Medical Group, Saint George, Utah, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Evergreen Health Infectious Disease, Kirkland, Washington, United States",-122.1786164,47.715878,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Evergreen Health Infectious Disease, Kirkland, Washington, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Swedish Hospital Medical Center, Seattle, Washington, United States",-122.3795882,47.667469,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Swedish Hospital Medical Center, Seattle, Washington, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada",-79.85409159999999,43.2624646,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",-79.7743193,43.2218746,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University Health Network, Toronto, Ontario, Canada",-79.38761810000001,43.6598777,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University Health Network, Toronto, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Clinical Research Institute of Montreal, Montreal, Quebec, Canada",-73.5761859,45.513589,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Clinical Research Institute of Montreal, Montreal, Quebec, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark",12.5667877,55.6960841,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hvidovre Hospital, Hvidovre, Denmark",12.470292,55.648779,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hvidovre Hospital, Hvidovre, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Odense Universitetshospital, Odense C, Denmark",10.3675736,55.3850091,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Odense Universitetshospital, Odense C, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Sjællands Universitetshospital, Roskilde, Roskilde, Denmark",12.0903485,55.6361646,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Sjællands Universitetshospital, Roskilde, Roskilde, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France",-1.4118805,46.6677714,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Centre Hospitalier et Universitaire de Limoges, Limoges, France",1.2357132,45.812311,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Centre Hospitalier et Universitaire de Limoges, Limoges, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hôpital de La Croix Rousse, Lyon, France",4.8308236,45.7818414,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hôpital de La Croix Rousse, Lyon, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hotel Dieu - Nantes, Nantes, France",-1.5545498,47.2107575,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hotel Dieu - Nantes, Nantes, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hopital de la Pitie Salpetriere, Paris, France",2.3650429,48.8370792,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hopital de la Pitie Salpetriere, Paris, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"HOPITAL COCHIN university hospital, Paris, France",2.3402667,48.8368937,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />HOPITAL COCHIN university hospital, Paris, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"CHRU de Tours, Pharmacie, Tours, France",0.6803135,47.389633,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />CHRU de Tours, Pharmacie, Tours, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitatsklinikum Dusseldorf, Dusseldorf, Germany",6.788855099999999,51.1987065,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitatsklinikum Dusseldorf, Dusseldorf, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Medizinische Hochschule Hannover, Hannover, Germany",9.804956899999999,52.3835661,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Medizinische Hochschule Hannover, Hannover, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany",10.1406978,54.3298132,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Uniklinik Köln, Köln, Germany",6.917063499999999,50.9234823,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Uniklinik Köln, Köln, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"LMU Klinikum der Universitat Munchen, Munchen, Germany",11.4699801,48.1106346,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />LMU Klinikum der Universitat Munchen, Munchen, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy",14.2207009,40.8677625,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy",12.4564793,41.866501,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy",9.638066,45.686107,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy",9.1230078,45.5192174,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy",9.2597899,45.6018705,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy",9.1488319,45.1962179,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Amphia Ziekenhuis, Breda, Netherlands",4.7628566,51.57417,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Amphia Ziekenhuis, Breda, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands",5.0789414,52.0249593,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Erasmus MC, Rotterdam, Netherlands",4.470303700000001,51.9112533,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Erasmus MC, Rotterdam, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",5.179913099999999,52.0865646,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitair Medisch Centrum Utrecht, Utrecht, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain",2.1042573,41.3448959,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitari Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitari Vall d'Hebron, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario La Paz, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario Ramon y Cajal, Madrid, Spain",-3.6951156,40.48760430000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario Ramon y Cajal, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital General Universitario Gregorio Maranon, Madrid, Spain",-3.6724986,40.4185038,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital General Universitario Gregorio Maranon, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain",-3.6667259,40.4902031,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom",-4.321016,55.883619,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom",-1.5528918,53.8025196,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University College Hospital, London, United Kingdom",-0.1363551,51.5250834,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University College Hospital, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Royal Free Hospital, London, United Kingdom",-0.1659994,51.55314749999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Royal Free Hospital, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St George's Clinical Research Facility, London, United Kingdom",-0.2343059,51.516825,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St George's Clinical Research Facility, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Imperial College London, London, United Kingdom",-0.1748772,51.49879970000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Imperial College London, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"North Manchester General Hospital, Manchester, United Kingdom",-2.2301193,53.5184925,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />North Manchester General Hospital, Manchester, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Salford Royal Hospital, Salford, United Kingdom",-2.3238955,53.487482,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04320615,"<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Salford Royal Hospital, Salford, United Kingdom"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mayo Clinic - Arizona, Phoenix, Arizona, United States",-111.9544986,33.6583608,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mayo Clinic - Arizona, Phoenix, Arizona, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Univ of AZ Coll of Med, Tucson, Arizona, United States",-110.9461054,32.2410865,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Univ of AZ Coll of Med, Tucson, Arizona, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"St. Jude Medical Center, Fullerton, California, United States",-117.9272201,33.8943451,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />St. Jude Medical Center, Fullerton, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"LAC + USC Medical Center, Los Angeles, California, United States",-118.2075585,34.0575334,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />LAC + USC Medical Center, Los Angeles, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"USC Keck Medical Center of USC, Los Angeles, California, United States",-118.2016181,34.0621498,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />USC Keck Medical Center of USC, Los Angeles, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Norwalk Hospital, Norwalk, Connecticut, United States",-73.42227489999999,41.1117461,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Norwalk Hospital, Norwalk, Connecticut, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Medstar Georgetown University Hospital, Washington, District of Columbia, United States",-77.0751693,38.911464,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Medstar Georgetown University Hospital, Washington, District of Columbia, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University of Florida; Health Science Center, Jacksonville, Florida, United States",-81.6634784,30.347113,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University of Florida; Health Science Center, Jacksonville, Florida, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mayo Clinic, Jacksonville, Florida, United States",-81.44514559999999,30.2626481,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mayo Clinic, Jacksonville, Florida, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Advocate Christ Medical Center, Oak Lawn, Illinois, United States",-87.73278239999999,41.7217943,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Advocate Christ Medical Center, Oak Lawn, Illinois, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Advocate Lutheran General Hospital, Park Ridge, Illinois, United States",-87.8476325,42.0385102,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Advocate Lutheran General Hospital, Park Ridge, Illinois, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"MedPharmics, Metairie, Louisiana, United States",-90.18101709999999,30.01050529999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />MedPharmics, Metairie, Louisiana, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University of Maryland, Baltimore, Maryland, United States",-76.6257057,39.2892017,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University of Maryland, Baltimore, Maryland, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Renown Institute for Heart & Vascular Health, Reno, Nevada, United States",-119.7952114,39.52552,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Renown Institute for Heart & Vascular Health, Reno, Nevada, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"St Joseph's Regional Medical Center, Wayne, New Jersey, United States",-74.1653704,40.9028953,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />St Joseph's Regional Medical Center, Wayne, New Jersey, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"SUNY Downstate Medical Center., Brooklyn, New York, United States",-73.9456988,40.65529340000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />SUNY Downstate Medical Center., Brooklyn, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States",-73.9357942,41.6943079,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Vassar Brothers Medical Center, Poughkeepsie, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",-80.2791958,36.1355052,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mercy St. Vincent Medical Center, Toledo, Ohio, United States",-83.54290449999999,41.6686144,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mercy St. Vincent Medical Center, Toledo, Ohio, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Lehigh Valley Health Network, Allentown, Pennsylvania, United States",-75.5241629,40.5667553,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Lehigh Valley Health Network, Allentown, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States",-80.00403179999999,40.4425172,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Medical University of South Carolina, Charleston, South Carolina, United States",-79.9478413,32.7850493,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Medical University of South Carolina, Charleston, South Carolina, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Houston Methodist Hospital, Houston, Texas, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States",-95.3889215,29.7020838,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Michael E. DeBakey VA Medical Center, Houston, Texas, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",-95.6309922,29.5891707,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020",NA,https://ClinicalTrials.gov/show/NCT04363736,"<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States"
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,NCT04332913,"Ospedale San Salvatore, L'Aquila, Italy",13.3532128,42.3659463,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,20,TOSCA,Recruiting,No Results Available,COVID-19 Pneumonia,NA,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases",University of L'Aquila,All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,0064468/20,"April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",NA,"April 13, 2020",NA,https://ClinicalTrials.gov/show/NCT04332913,"<b>Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia</b><br /><i>Recruiting, n = 30</i><br />Ospedale San Salvatore, L'Aquila, Italy"
Tocilizumab Treatment in Patients With COVID-19,NCT04363853,"National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",-99.16038309999999,19.2892389,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,21,NA,Recruiting,No Results Available,Sars-CoV2,Drug: Tocilizumab,Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography,Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,200,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INF-3343-20-22-1,"April 1, 2020","June 1, 2020","August 1, 2020","April 27, 2020",NA,"April 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04363853,"<b>Tocilizumab Treatment in Patients With COVID-19</b><br /><i>Recruiting, n = 200</i><br />National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States",-117.024154,32.6172649,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />eStudySite - Chula Vista - PPDS, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States",-93.7608764,32.4807365,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Boston Medical Center, Boston, Massachusetts, United States",-71.0731311,42.3344959,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Boston Medical Center, Boston, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Baystate Medical Center, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Baystate Medical Center, Springfield, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"St. Michael'S Medical Center, Newark, New Jersey, United States",-74.17522029999999,40.7443458,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />St. Michael'S Medical Center, Newark, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409262,"<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Quirónsalud Barcelona, Barcelona, Spain",2.1385079,41.415745,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Quirónsalud Barcelona, Barcelona, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain",0.6134759,41.62665,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.48760430000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Ruber Juan Bravo, Madrid, Spain",-3.677653799999999,40.4327229,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Ruber Juan Bravo, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Ruber Internacional, Madrid, Spain",-3.7156662,40.4894832,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Ruber Internacional, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Arnau de Vilanova-Lliria, Valencia, Spain",-0.4033429,39.4907502,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Arnau de Vilanova-Lliria, Valencia, Spain"
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitario Doctor Peset, Valencia, Spain",-0.393695,39.4524937,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04335305,"<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitario Doctor Peset, Valencia, Spain"
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,NCT04306705,"Tongji Hospital, Wuhan, Hubei, China",114.309504,30.552113,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,24,TACOS,Recruiting,No Results Available,Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab,Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy,"Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells",Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",NA,120,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,WHTJCOVID-19,"February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",NA,"March 17, 2020",NA,https://ClinicalTrials.gov/show/NCT04306705,"<b>Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19</b><br /><i>Recruiting, n = 120</i><br />Tongji Hospital, Wuhan, Hubei, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Guiqiang Wang, Beijing, Beijing, China",116.4073963,39.90419989999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Guiqiang Wang, Beijing, Beijing, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Peking University First Hospital, Beijing, Beijing, China",116.380416,39.931765,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Peking University First Hospital, Beijing, Beijing, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Ezhou Central Hospital, Wuhan, Hubei, China",114.8819099,30.3987825,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Ezhou Central Hospital, Wuhan, Hubei, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China",114.305539,30.592849,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Jinyintan Hospital of Wuhan, Wuhan, Hubei, China",114.2868443,30.6668794,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Jinyintan Hospital of Wuhan, Wuhan, Hubei, China"
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Wuhan Pulmonary Hospital, Wuhan, Hubei, China",114.305539,30.592849,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020",NA,https://ClinicalTrials.gov/show/NCT04310228,"<b>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</b><br /><i>Recruiting, n = 150</i><br />Wuhan Pulmonary Hospital, Wuhan, Hubei, China"
Tocilizumab for Patients With Cancer and COVID-19 Disease,NCT04370834,"National Cancer Institute, Rockville, Maryland, United States",-77.1974895,39.1036356,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,26,NA,Recruiting,No Results Available,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Pneumonitis|Severe Acute Respiratory Distress Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed,Biological: Tocilizumab,Frequency of response|Length of time from level of care to step down level of care|Survival,National Cancer Institute (NCI),All,"2 Years and older   (Child, Adult, Older Adult)",Phase 2,200,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,NCI-2020-02987|TRC-10446,"May 28, 2020","January 1, 2022","January 1, 2022","May 1, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04370834,"<b>Tocilizumab for Patients With Cancer and COVID-19 Disease</b><br /><i>Recruiting, n = 200</i><br />National Cancer Institute, Rockville, Maryland, United States"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece",23.6653306,38.01659799999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece",20.8424173,39.620779,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece",21.7950459,38.2945759,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece",23.7315473,38.014229,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece",23.769038,37.992309,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece",23.7275388,37.9838096,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece",23.75975,37.9836396,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece",23.6653306,38.01659799999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece",23.7547649,37.84808719999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece",23.5323004,38.071821,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece",NA,NA,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, Larissa University Hospital, Larissa, Greece",22.4191254,39.63902239999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, Larissa University Hospital, Larissa, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece",23.7295198,37.93572109999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece",22.9586356,40.6372887,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece",22.9444191,40.6400629,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece",22.9617339,40.6116363,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",22.9600672,40.62955600000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020",NA,https://ClinicalTrials.gov/show/NCT04339712,"<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece"
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,NCT04315480,"Università Politecnica delle Marche, Ancona, AN, Italy",13.5139647,43.6173812,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,28,NA,"Active, not recruiting",No Results Available,SARS Pneumonia,Drug: Tocilizumab,arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death,Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,38,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCICOV-1,"March 12, 2020","April 9, 2020",May 2020,"March 19, 2020",NA,"April 13, 2020","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04315480,"<b>Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis</b><br /><i>Active, not recruiting, n = 38</i><br />Università Politecnica delle Marche, Ancona, AN, Italy"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Centre Léon Bérard, Lyon, Rhône, France",4.877716899999999,45.7412874,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />Centre Léon Bérard, Lyon, Rhône, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"CHU Clermont Ferrand, Clermont Ferrand, France",NA,NA,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />CHU Clermont Ferrand, Clermont Ferrand, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Centre Oscar Lambret, Lille, France",3.0325736,50.6124605,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />Centre Oscar Lambret, Lille, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />AP-HP Hôpital Saint Antoine, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP La Pitié Salpétrière, Paris, France",2.3650429,48.8370792,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />AP-HP La Pitié Salpétrière, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Hôpital Saint-Joseph, Paris, France",2.309933,48.829771,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />Hôpital Saint-Joseph, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Tenon, Paris, France",2.4019105,48.8661347,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />AP-HP Tenon, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Hôpital Bichat Claude Bernard, Paris, France",2.3317094,48.8988449,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />AP-HP Hôpital Bichat Claude Bernard, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"GH Diaconesses Croix Saint Simon, Paris, France",2.4087816,48.8541165,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />GH Diaconesses Croix Saint Simon, Paris, France"
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Gustave Roussy, Villejuif, France",2.3484483,48.79425879999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020",NA,https://ClinicalTrials.gov/show/NCT04333914,"<b>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</b><br /><i>Recruiting, n = 384</i><br />Gustave Roussy, Villejuif, France"
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),NCT04361552,"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",-84.3194393,33.7928615,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,31,NA,Recruiting,No Results Available,Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection,Other: Best Practice|Biological: Tocilizumab,7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay,Emory University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,180,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292,"May 30, 2020","May 30, 2022","May 30, 2022","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04361552,"<b>Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)</b><br /><i>Recruiting, n = 180</i><br />Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation",37.571717,55.731551,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation",37.80746269999999,55.7984686,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation",37.5286696,55.70393490000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation",37.80746269999999,55.7984686,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation",30.3609096,59.9310584,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",30.3609096,59.9310584,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020",NA,https://ClinicalTrials.gov/show/NCT04380519,"<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Sint-Jan Brugge, Brugge, Belgium",3.1930172,51.2208468,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Sint-Jan Brugge, Brugge, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Saint-Pierre, Brussels, Belgium",4.345909,50.83448680000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Saint-Pierre, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Erasmus University Hospital, Brussels, Belgium",4.265892,50.813446,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Erasmus University Hospital, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Saint-Luc, Brussels, Belgium",4.4520234,50.8529013,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Saint-Luc, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Antwerp, Edegem, Belgium",4.4108109,51.15769299999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Antwerp, Edegem, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Ziekenhuis Oost-Limurg, Genk, Belgium",5.517904,50.957107,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Ziekenhuis Oost-Limurg, Genk, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Sint-Lucas, Gent, Belgium",3.7217947,51.0601558,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Sint-Lucas, Gent, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Ghent, Gent, Belgium",3.7261488,51.0243757,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Ghent, Gent, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Jessa ZH, Hasselt, Belgium",5.3473957,50.9085411,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Jessa ZH, Hasselt, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Brussels, Jette, Belgium",4.3086096,50.88780939999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Brussels, Jette, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"CHU Tivoli, La Louvière, Belgium",4.2076091,50.477916,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />CHU Tivoli, La Louvière, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"CHR de la Citadelle, Liège, Belgium",5.577856499999999,50.6521064,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />CHR de la Citadelle, Liège, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Liège, Liège, Belgium",5.5919769,50.6459547,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Liège, Liège, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium",4.5609799,50.667795,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Delta, Roeselare, Belgium",3.1233251,50.9539257,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04330638,"<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Delta, Roeselare, Belgium"
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,NCT04322773,"Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark",12.5401313,55.7140142,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,34,TOCIVID,Recruiting,No Results Available,Corona Virus Disease,Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care,Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events,Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APPI2-CV-2020-01,"April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04322773,"<b>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</b><br /><i>Recruiting, n = 200</i><br />Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark"
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,NCT04322773,"Hillerød Hospital, Hillerød, Denmark",12.326221,55.930868,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,34,TOCIVID,Recruiting,No Results Available,Corona Virus Disease,Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care,Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events,Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APPI2-CV-2020-01,"April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",NA,"April 7, 2020",NA,https://ClinicalTrials.gov/show/NCT04322773,"<b>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</b><br /><i>Recruiting, n = 200</i><br />Hillerød Hospital, Hillerød, Denmark"
Randomised Evaluation of COVID-19 Therapy,NCT04381936,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",-1.2151574,51.7516232,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,36,RECOVERY,Recruiting,No Results Available,Severe Acute Respiratory Syndrome,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab,All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO,"University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding",All,"Child, Adult, Older Adult",Phase 2|Phase 3,12000,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NDPHRECOVERY|2020-001113-21|ISRCTN50189673,"March 19, 2020",December 2020,June 2021,"May 11, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04381936,"<b>Randomised Evaluation of COVID-19 Therapy</b><br /><i>Recruiting, n = 12000</i><br />Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP- Hopital Tenon, Paris, France",2.4019105,48.8661347,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP- Hopital Tenon, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Beaujon, Paris, France",2.3083004,48.9082554,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP - Beaujon, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Bichat, Paris, France",2.3317094,48.8988449,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP - Bichat, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Hopital Necker, Paris, France",2.3147044,48.845868,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP - Hopital Necker, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Pitié Salpêtrière, Paris, France",2.3650429,48.8370792,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP - Pitié Salpêtrière, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Saint Louis, Paris, France",2.3697699,48.87340649999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />APHP - Saint Louis, Paris, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"CHU Strasbourg, Strasbourg, France",7.707166699999999,48.5929237,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />CHU Strasbourg, Strasbourg, France"
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"Institut Gustave Roussy, Villejuif, France",2.3484483,48.79425879999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04331808,"<b>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</b><br /><i>Active, not recruiting, n = 228</i><br />Institut Gustave Roussy, Villejuif, France"
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,NCT04366206,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,38,NA,Recruiting,No Results Available,COVID|SARS-CoV 2,NA,Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation,Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere,All,"Child, Adult, Older Adult",NA,143,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GHTRB-2020-01,"March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04366206,"<b>Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est</b><br /><i>Recruiting, n = 143</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,NCT04366206,"Groupe Hospitalier Pitie Salpetriere, Paris, France",2.3650429,48.8370792,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,38,NA,Recruiting,No Results Available,COVID|SARS-CoV 2,NA,Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation,Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere,All,"Child, Adult, Older Adult",NA,143,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GHTRB-2020-01,"March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",NA,"April 28, 2020",NA,https://ClinicalTrials.gov/show/NCT04366206,"<b>Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est</b><br /><i>Recruiting, n = 143</i><br />Groupe Hospitalier Pitie Salpetriere, Paris, France"
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,NCT04409522,"Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",51.3435135,35.7091321,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,39,NA,Recruiting,No Results Available,COVID-19,Drug: Melatonin|Drug: The usual treatment,Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route,Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IR.BMSU.REC.1399.039,"May 12, 2020","June 5, 2020","September 25, 2020","June 1, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04409522,"<b>Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients</b><br /><i>Recruiting, n = 55</i><br />Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.28119420000002,2.9321351,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.09571559999999,4.648948499999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04359095,"<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NCT04347031,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,41,NA,"Active, not recruiting",No Results Available,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,Burnasyan Federal Medical Biophysical Center,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL-01/20,"April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04347031,"<b>A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,42,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04365764,"<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",2.5720537,48.8984523,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,42,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020",NA,https://ClinicalTrials.gov/show/NCT04365764,"<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,NCT04388514,"Dott. Amato De Monte, Udine, Italy",13.1207067,46.2170583,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,43,CORMOR,Recruiting,No Results Available,SARS-CoV-2 Respiratory Failure,Procedure: Medical Ozone procedure,Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome,"Azienda Sanitaria-Universitaria Integrata di Udine|Fondazione Toscana Gabriele Monasterio|Policlinico Militare, Roma - Italy|Ospedale San Liberatore di Atri|Ospedale Umberto I di Torino|Università di Siena|Ospedale Civile di Lucca|Ospedale di Siracusa|Azienda Sanitaria Locale di Vercelli",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CIG: Z7C2CA5837,"April 8, 2020","October 8, 2020","October 8, 2020","May 14, 2020",NA,"May 14, 2020","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04388514,"<b>Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure</b><br /><i>Recruiting, n = 90</i><br />Dott. Amato De Monte, Udine, Italy"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Sant Joan de Reus, Reus, Tarragona, Spain",1.1232334,41.1443624,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,44,NA,Recruiting,No Results Available,"Pneumonia, Viral",Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1,Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IPACOVID,"May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04380818,"<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Sant Joan de Reus, Reus, Tarragona, Spain"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Del Mar, Barcelona, Spain",2.1941912,41.38389069999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,44,NA,Recruiting,No Results Available,"Pneumonia, Viral",Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1,Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IPACOVID,"May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04380818,"<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Del Mar, Barcelona, Spain"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",-3.6667259,40.4902031,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,44,NA,Recruiting,No Results Available,"Pneumonia, Viral",Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1,Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IPACOVID,"May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",NA,"June 1, 2020",NA,https://ClinicalTrials.gov/show/NCT04380818,"<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Universitario Madrid Sanchinarro, Madrid, Spain"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St Vincent's Hospital Sydney, Sydney, New South Wales, Australia",151.2207522,-33.8805454,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St Vincent's Hospital Sydney, Sydney, New South Wales, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia",151.1829669,-33.8891822,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal North Shore Hospital, Sydney, New South Wales, Australia",151.1918521,-33.8214962,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal North Shore Hospital, Sydney, New South Wales, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Nepean Hospital, Sydney, New South Wales, Australia",150.7137515,-33.7588094,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Nepean Hospital, Sydney, New South Wales, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Wollongong Hospital, Sydney, New South Wales, Australia",150.88353,-34.42476,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Wollongong Hospital, Sydney, New South Wales, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Darwin Hospital,, Darwin, Northern Territory, Australia",130.882915,-12.3554775,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Darwin Hospital,, Darwin, Northern Territory, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Sunshine Coast University Hospital, Birtinya, Queensland, Australia",153.1137558,-26.7468526,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Sunshine Coast University Hospital, Birtinya, Queensland, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Princess Alexandra Hospital, Brisbane, Queensland, Australia",153.0332192,-27.4990274,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Princess Alexandra Hospital, Brisbane, Queensland, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Logan Hospital, Brisbane, Queensland, Australia",153.1418031,-27.6700261,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Logan Hospital, Brisbane, Queensland, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Toowoomba Hospital, Toowoomba, Queensland, Australia",151.9442798,-27.5698357,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Toowoomba Hospital, Toowoomba, Queensland, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The Queen Elizabeth Hospital, Adelaide, South Australia, Australia",138.5330755,-34.8837417,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />The Queen Elizabeth Hospital, Adelaide, South Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Bendigo Hospital, Bendigo, Victoria, Australia",144.280769,-36.749617,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Bendigo Hospital, Bendigo, Victoria, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hosptial Geelong, Geelong, Victoria, Australia",144.3656239,-38.1512248,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hosptial Geelong, Geelong, Victoria, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The Alfred Hospital, Melbourne, Victoria, Australia",144.9819197,-37.8456704,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />The Alfred Hospital, Melbourne, Victoria, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Melbourne Hospital, Melbourne, Victoria, Australia",144.95617,-37.7989153,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Melbourne Hospital, Melbourne, Victoria, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia",144.9750364,-37.807357,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Perth Hospital, Perth, Western Australia, Australia",115.8663522,-31.9537557,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Perth Hospital, Perth, Western Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",115.8170819,-31.9669399,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St John of God Hospital Midland, Perth, Western Australia, Australia",116.0071519,-31.8945381,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St John of God Hospital Midland, Perth, Western Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Fiona Stanley Hospital, Perth, Western Australia, Australia",115.8460302,-32.070223,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Fiona Stanley Hospital, Perth, Western Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St John of God Hospital Murdoch, Perth, Western Australia, Australia",115.8448198,-32.0679279,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St John of God Hospital Murdoch, Perth, Western Australia, Australia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"AZ Sint-Jan, Brugge, Belgium",3.1934588,51.2201147,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />AZ Sint-Jan, Brugge, Belgium"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium",4.4401814,50.430972,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitair Ziekenhuis Antwerp, Edegem, Belgium",4.4108109,51.15769299999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitair Ziekenhuis Antwerp, Edegem, Belgium"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitair Ziekenhuis Gent, Gent, Belgium",3.7261488,51.0243757,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitair Ziekenhuis Gent, Gent, Belgium"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Joseph's Healthcare Hamilton, Hamilton, Canada",-79.8702177,43.2491399,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St. Joseph's Healthcare Hamilton, Hamilton, Canada"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada",-71.9239001,45.39802299999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Michael's Hospital Unity Health Toronto, Toronto, Canada",-79.3776369,43.6529691,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St. Michael's Hospital Unity Health Toronto, Toronto, Canada"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"General County Hospital Požega, Požega, Croatia",17.699313,45.34406999999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />General County Hospital Požega, Požega, Croatia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Centre Zagreb, Zagreb, Croatia",16.005712,45.8247665,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital Centre Zagreb, Zagreb, Croatia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital for Infectious Diseases, Zagreb, Croatia",15.9801721,45.8297653,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital for Infectious Diseases, Zagreb, Croatia"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany",13.3214126,52.4426162,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany",13.3766245,52.5264618,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Vivantes Klinikum Neukölln, Berlin, Germany",13.4584758,52.4390139,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Vivantes Klinikum Neukölln, Berlin, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Köln, Cologne, Germany",6.917063499999999,50.9234823,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitätsklinikum Köln, Cologne, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Frankfurt, Frankfurt, Germany",8.6616969,50.0951726,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitätsklinikum Frankfurt, Frankfurt, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany",9.974533,53.59081159999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Medizinische Hochschule Hannover, Hannover, Germany",9.804956899999999,52.3835661,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Medizinische Hochschule Hannover, Hannover, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Jena, Jena, Germany",11.5787572,50.9289028,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitätsklinikum Jena, Jena, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Leipzig, Leipzig, Germany",12.3865502,51.3309373,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitätsklinikum Leipzig, Leipzig, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitäts Klinikum Tübingen, Tübingen, Germany",9.0398494,48.529687,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitäts Klinikum Tübingen, Tübingen, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Würzburg, Würzburg, Germany",9.9583849,49.8071108,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Universitätsklinikum Würzburg, Würzburg, Germany"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Jósa András County Hospital, Nyíregyháza, Hungary",21.7298853,47.9505018,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Jósa András County Hospital, Nyíregyháza, Hungary"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary",17.9104293,47.090947,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Almási Balogh Pál Kórház, Ózd, Hungary",20.2916106,48.2092299,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Almási Balogh Pál Kórház, Ózd, Hungary"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Beaumont Hospital, Dublin, Ireland",-6.2233019,53.3904777,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Beaumont Hospital, Dublin, Ireland"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Vincent's University Hospital, Dublin, Ireland",-6.214048,53.31699,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />St. Vincent's University Hospital, Dublin, Ireland"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Galway, Galway, Ireland",-9.066112,53.276846,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital Galway, Galway, Ireland"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Meander Medisch Centrum, Amersfoort, Netherlands",5.3698679,52.1706432,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Meander Medisch Centrum, Amersfoort, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands",5.277171,51.6850355,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Martini Hospital Groningen, Groningen, Netherlands",6.551730099999999,53.1916514,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Martini Hospital Groningen, Groningen, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Groningen, Groningen, Netherlands",6.577026099999999,53.220974,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Medical Center Groningen, Groningen, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Leiden University Medical Center, Leiden, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands",5.830246,51.817376,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Radboud University Medical Center, Nijmegen, Netherlands",5.8611812,51.8235728,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Radboud University Medical Center, Nijmegen, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Utrecht, Utrecht, Netherlands",5.179913099999999,52.0865646,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Medical Center Utrecht, Utrecht, Netherlands"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"North Shore Hospital, Auckland, New Zealand",174.7573882,-36.7811891,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />North Shore Hospital, Auckland, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"CVICU, Auckland City Hospital, Auckland, New Zealand",174.7691264,-36.8604597,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />CVICU, Auckland City Hospital, Auckland, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"DCCM, Auckland City Hospital, Auckland, New Zealand",174.7695893,-36.8605068,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />DCCM, Auckland City Hospital, Auckland, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Middlemore Hospital, Auckland, New Zealand",174.839542,-36.96339,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Middlemore Hospital, Auckland, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Christchurch Hospital, Christchurch, New Zealand",172.625825,-43.534003,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Christchurch Hospital, Christchurch, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Waikato Hospital, Hamilton, New Zealand",175.2824626,-37.8050951,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Waikato Hospital, Hamilton, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Rotorua Hospital, Rotorua, New Zealand",176.248148,-38.131112,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Rotorua Hospital, Rotorua, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Tauranga Hospital, Tauranga, New Zealand",176.1479153,-37.7079139,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Tauranga Hospital, Tauranga, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Wellington Regional Hospital, Wellington, New Zealand",174.77937,-41.3082838,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Wellington Regional Hospital, Wellington, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Whangarei Hospital, Whangarei, New Zealand",174.3031392,-35.7350292,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Whangarei Hospital, Whangarei, New Zealand"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Centro Hospitalar do Medio Tejo, Abrantes, Portugal",-8.198573399999999,39.4560473,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Centro Hospitalar do Medio Tejo, Abrantes, Portugal"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Hospital Lusíadas Lisbon, Lisboa, Portugal",-9.1795052,38.7493782,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Hospital Lusíadas Lisbon, Lisboa, Portugal"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania",26.1025384,44.4267674,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain",2.1940517,41.3853788,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Hospital Universitario Reina Sofia, Córdoba, Spain",-4.797799599999999,37.8677597,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Hospital Universitario Reina Sofia, Córdoba, Spain"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom",-1.1111343,51.2803791,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Southmead Hospital, Bristol, United Kingdom",-2.5916111,51.4968176,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Southmead Hospital, Bristol, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Coventry, Coventry, United Kingdom",-1.4376872,52.4211586,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital Coventry, Coventry, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Darlington Memorial Hospital, Darlington, United Kingdom",-1.5643608,54.530337,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Darlington Memorial Hospital, Darlington, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital of North Durham, Durham, United Kingdom",-1.5933009,54.7885266,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital of North Durham, Durham, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom",-1.5528918,53.8025196,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom",0.4840182,51.2750079,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The James Cook University Hospital, Middlesbrough, United Kingdom",-1.2146772,54.5512379,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />The James Cook University Hospital, Middlesbrough, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Milton Keynes University Hospital, Milton Keynes, United Kingdom",-0.7357762,52.0269973,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Milton Keynes University Hospital, Milton Keynes, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Northampton General Hospital, Northampton, United Kingdom",-0.8842779,52.23613659999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Northampton General Hospital, Northampton, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",-1.1850038,52.9435955,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Poole Hospital NHS Foundation Trust, Poole, United Kingdom",-1.9737732,50.7213346,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Poole Hospital NHS Foundation Trust, Poole, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom",-1.0700809,50.84998299999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Berkshire Hospital, Reading, United Kingdom",-0.9581843999999999,51.4492924,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Berkshire Hospital, Reading, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital of North Tees, Stockton-on-Tees, United Kingdom",-1.3472709,54.58249679999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />University Hospital of North Tees, Stockton-on-Tees, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Cornwall Hospital, Truro, United Kingdom",-5.0922396,50.2662301,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Royal Cornwall Hospital, Truro, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom",0.3069464,51.1483335,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom"
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"York Hospital, York, United Kingdom",-1.0835656,53.9699889,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020",NA,https://ClinicalTrials.gov/show/NCT02735707,"<b>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</b><br /><i>Recruiting, n = 7100</i><br />York Hospital, York, United Kingdom"
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,NCT04349410,"FHHI-OI-Camelot; QME, Los Angeles, California, United States",-118.4595285,34.0501689,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,46,FMTVDM,Enrolling by invitation,No Results Available,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status,The Camelot Foundation,All,"Child, Adult, Older Adult",Phase 2|Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FMTVDM2020,"April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",NA,"April 17, 2020",NA,https://ClinicalTrials.gov/show/NCT04349410,"<b>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</b><br /><i>Enrolling by invitation, n = 500</i><br />FHHI-OI-Camelot; QME, Los Angeles, California, United States"
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,NCT04374539,"Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,47,REP-COVID,Recruiting,No Results Available,Coronavirus,Biological: Plasma exchange|Drug: Standar medical treatmen,Impact of plasma exchange,Fundacion Clinic per a la Recerca Biomédica,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,116,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001722-66,"April 29, 2020","May 5, 2021","August 29, 2021","May 5, 2020",NA,"May 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04374539,"<b>Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial</b><br /><i>Recruiting, n = 116</i><br />Hospital Clinic i Provincial de Barcelona, Barcelona, Spain"
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NCT04346693,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,48,NA,"Active, not recruiting",No Results Available,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study,Burnasyan Federal Medical Biophysical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAL-05-04-2020,"April 8, 2020",December 2020,December 2020,"April 15, 2020",NA,"May 27, 2020",NA,https://ClinicalTrials.gov/show/NCT04346693,"<b>An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Study of Open Label Losartan in COVID-19,NCT04335123,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05634999999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,49,NA,Recruiting,No Results Available,COVID-19,Drug: Losartan,"Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg",University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00145514,"March 25, 2020",September 2020,October 2020,"April 6, 2020",NA,"April 24, 2020",NA,https://ClinicalTrials.gov/show/NCT04335123,"<b>Study of Open Label Losartan in COVID-19</b><br /><i>Recruiting, n = 50</i><br />University of Kansas Medical Center, Kansas City, Kansas, United States"
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,NCT04394182,"Hospital La Milagrosa, GenesisCare, Madrid, Spain",-3.6959039,40.4369834,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,50,ULTRA-COVID,Recruiting,No Results Available,"Pneumonia, Viral|Cytokine Storm",Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab,Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity,Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20.4.1597-GHM,"April 21, 2020","December 31, 2020","April 21, 2021","May 19, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04394182,"<b>Ultra Low Doses of Therapy With Radiation Applicated to COVID-19</b><br /><i>Recruiting, n = 15</i><br />Hospital La Milagrosa, GenesisCare, Madrid, Spain"
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,NCT04394182,"Hospital Vithas Valencia Consuelo, Valencia, Spain",-0.3867362,39.4607499,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,50,ULTRA-COVID,Recruiting,No Results Available,"Pneumonia, Viral|Cytokine Storm",Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab,Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity,Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20.4.1597-GHM,"April 21, 2020","December 31, 2020","April 21, 2021","May 19, 2020",NA,"May 19, 2020",NA,https://ClinicalTrials.gov/show/NCT04394182,"<b>Ultra Low Doses of Therapy With Radiation Applicated to COVID-19</b><br /><i>Recruiting, n = 15</i><br />Hospital Vithas Valencia Consuelo, Valencia, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain",-6.1486211,36.699219,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Puerto Real, Puerto Real, Cádiz, Spain",-6.1515222,36.5200097,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Puerto Real, Puerto Real, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Costa del Sol, Marbella, Málaga, Spain",-4.827745,36.5079652,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Costa del Sol, Marbella, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Torrecárdenas, Almería, Spain",-2.4411846,36.8626932,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Torrecárdenas, Almería, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Puerta del Mar, Cádiz, Spain",-6.278229899999999,36.5089533,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Puerta del Mar, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Virgen de las Nieves, Granada, Spain",-3.6099419,37.1885496,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Virgen de las Nieves, Granada, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. San Cecilio, Granada, Spain",-3.6050952,37.1466315,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. San Cecilio, Granada, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Juan Ramón Jiménez, Huelva, Spain",-6.926966999999999,37.2798933,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Juan Ramón Jiménez, Huelva, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Regional U. de Málaga, Málaga, Spain",-4.4498416,36.7231736,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Regional U. de Málaga, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Virgen de la Victoria, Málaga, Spain",-4.4780498,36.7183379,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Virgen de la Victoria, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Unversitario Virgen Macarena, Sevilla, Spain",-5.986478,37.4065718,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Unversitario Virgen Macarena, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Universitario Virgen del Rocío, Sevilla, Spain",-5.9803696,37.3618418,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Universitario Virgen del Rocío, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Nuestra Señora de Valme, Sevilla, Spain",-5.9712578,37.3188416,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Nuestra Señora de Valme, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital San Juan de Dios, Sevilla, Spain",-5.9691386,37.3816501,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020",NA,https://ClinicalTrials.gov/show/NCT04366245,"<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital San Juan de Dios, Sevilla, Spain"
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,NCT04392414,"Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",-77.1043789,39.0025272,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,52,NA,Recruiting,No Results Available,COVID-19,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),"The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CovPlas-Covid19,"May 1, 2020","August 1, 2020","September 15, 2020","May 18, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04392414,"<b>Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 60</i><br />Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation"
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,NCT04414631,"University Hospital Basel, Division of Internal Medicine, Basel, Switzerland",7.5830579,47.5621796,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,53,NA,Not yet recruiting,No Results Available,Coronavirus Infections,Drug: Conestat alfa,Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg),"University Hospital, Basel, Switzerland|Pharming Technologies B.V.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-01252; me20Osthoff3,June 2020,June 2021,July 2021,"June 4, 2020",NA,"June 4, 2020",NA,https://ClinicalTrials.gov/show/NCT04414631,"<b>Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19</b><br /><i>Not yet recruiting, n = 120</i><br />University Hospital Basel, Division of Internal Medicine, Basel, Switzerland"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",-92.29232280000001,34.7390944,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Colorado University Denver, Aurora, Colorado, United States",-105.002304,39.7457714,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Colorado University Denver, Aurora, Colorado, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States",-75.5552234,39.7793465,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States",-81.66413089999999,30.3485024,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States",-157.8334591,21.2998428,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States",-87.6218344,41.8962223,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States",-86.1811403,39.7765068,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05634999999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Kansas Medical Center, Kansas City, Kansas, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Wesley Medical Center, Wichita, Kansas, United States",-97.29818329999999,37.6953199,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Wesley Medical Center, Wichita, Kansas, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States",-85.7494773,38.2482108,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Tulane University Health Science Center, New Orleans, Louisiana, United States",-90.0791663,29.9529352,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Tulane University Health Science Center, New Orleans, Louisiana, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States",-90.10432109999999,29.9376843,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Minnesota, Minneapolis, Minnesota, United States",-93.2277285,44.97399,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Minnesota, Minneapolis, Minnesota, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Mississippi Medical Center, Jackson, Mississippi, United States",-90.1736583,32.3299207,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Mississippi Medical Center, Jackson, Mississippi, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Childrens Mercy Hospital, Kansas City, Missouri, United States",-94.5771759,39.08387889999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Childrens Mercy Hospital, Kansas City, Missouri, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Nebraska Medical Center, Omaha, Nebraska, United States",-95.9759165,41.2548549,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of Nebraska Medical Center, Omaha, Nebraska, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.67536399999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of New Mexico Health Science Center, Albuquerque, New Mexico, United States",-106.6182356,35.0903535,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of New Mexico Health Science Center, Albuquerque, New Mexico, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Kravis Children's Hospital at Mt. Sinai, New York, New York, United States",-73.95391699999999,40.7900948,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Kravis Children's Hospital at Mt. Sinai, New York, New York, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",-79.0469134,35.9049122,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Duke University Health System, Durham, North Carolina, United States",-78.9375709,36.0070331,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Duke University Health System, Durham, North Carolina, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",-84.5014413,39.14063429999999,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States",-97.5816919,35.5306526,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Oregon Health and Science University, Portland, Oregon, United States",-122.6891258,45.4963132,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Oregon Health and Science University, Portland, Oregon, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Rhode Island Hospital, Providence, Rhode Island, United States",-71.41105809999999,41.8090573,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Rhode Island Hospital, Providence, Rhode Island, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States",-79.9508927,32.7847341,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of South Carolina, Columbia, South Carolina, United States",-81.0299186,33.9937575,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University of South Carolina, Columbia, South Carolina, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States",-86.80248879999999,36.1393475,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Dell Children's Medical Center of Central Texas, Austin, Texas, United States",-97.7073463,30.3034562,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Dell Children's Medical Center of Central Texas, Austin, Texas, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Seattle Children's Hospital, Seattle, Washington, United States",-122.2819821,47.6628416,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Seattle Children's Hospital, Seattle, Washington, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University Wisconsin, Madison, Wisconsin, United States",-89.4124875,43.076592,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />University Wisconsin, Madison, Wisconsin, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.02212,43.0429926,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Medical College of Wisconsin, Milwaukee, Wisconsin, United States"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",-75.652152,45.40076680000001,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"The Hospital for Sick Children, Toronto, Ontario, Canada",-79.38730389999999,43.6573229,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />The Hospital for Sick Children, Toronto, Ontario, Canada"
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"CHU Sainte-Justine, Montréal, Quebec, Canada",-73.6239743,45.5032538,Tocilizumab,data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020",NA,https://ClinicalTrials.gov/show/NCT04278404,"<b>Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)</b><br /><i>Recruiting, n = 5000</i><br />CHU Sainte-Justine, Montréal, Quebec, Canada"
